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In this thesis, I have developed a novel zebrafish model of neurovascular coupling. Combining 
lightsheet imaging, compound transgenic zebrafish models and custom MATLAB based 
analysis pipelines, I characterised the neurovascular responses (neuronal calcium increases and 
change in red blood cell speed) in the optic tectum in response to visual stimulation. I 
determined the development stage at which neurovascular coupling in zebrafish larvae 
develops, followed by testing the requirement for nitric oxide or astrocyte cyclo-oxygenase in 
my model. I then used this model to investigate factors influencing neurovascular function. I 
first characterized the effect of glucose exposure and the role of nitric oxide in modulating 
neurovascular coupling. I then examined the effect of genetic mutation of Guanosine 
Triphosphate cyclohydrolase (an enzyme involved in nitric oxide and dopamine production in 
the brain) on neurovascular coupling. Finally, I have developed a minimal mathematical model 
of the neurovascular unit. To demonstrate the potential of this model I have simulated the effect 
of high blood glucose and low nitric oxide on neurovascular coupling and show this conforms 






The brain accounts for 2% of body weight but consumes 20% of cardiac output. Active neurons 
depend on increases in local cerebral blood flow (CBF) through neurovascular coupling (NVC) 
as first described by Roy and Sherrington (1). 
Many human diseases are associated with neurovascular dysfunction (2-5). Several studies 
have shown neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease are 
associated with reduced cerebral blood flow and neurovascular deficits (6-8). Although there 
is an increase in the number of drugs being discovered to treat various symptoms of such 
diseases, the fundamental mechanisms of these pathologies are not well understood, hindering 
the progress to find a cure for neurodegenerative diseases.  
Micro and macrovascular diseases such as hypertension, diabetes and stroke are major risk 
factors of neurodegenerative disorders (9-11). Recent studies have also demonstrated cerebral 
blood flow deficits in such vascular diseases suggesting the possibility of common pathological 
mechanisms between cardiovascular and neurological diseases.  
 
1.1 Neurovascular coupling 
Neurons, unlike other cells, possess limited energy reserves (12). Hence, it is essential that 
increased neuronal energy demands are rapidly met (spatially and temporally) by an increase 
in blood flow to supply the requisite oxygen and glucose to the neuron.  This process, termed 
NVC, results from crosstalk between the cellular elements of the neurovascular unit (NVU) 
(13). These neuronal activity-evoked changes in blood flow and oxygenation underlie 
functional neuroimaging techniques such as BOLD-fMRI (blood oxygen level dependent- 
functional magnetic resonance imaging) (14, 15).  
The NVU comprises neurons, astrocytes, pericytes, vascular smooth muscle cells (VSMCs) 
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and endothelial cells (ECs) (Figure 1-1 and Figure 1-2). Neurons depolarize in response to a 
stimulus and consume energy to restore their electrochemical gradients. Depolarization leads 
to release of synaptic neurotransmitters, which can act on post-synaptic neurons and 
surrounding astrocytes (16). Astrocytes in turn respond to neurotransmitters by increasing 
intracellular calcium, leading to release of vasodilators (16). Surrounding blood vessels dilate 
due to hyperpolarization of VSMCs and calcium increases in ECs (16), leading to increased 
local blood flow. Vasodilation can also be induced by mechanisms such as increased 
extracellular potassium or neuronal nitric oxide (NO) release (17). These mechanisms 
contribute to NVC, communicating the cerebral energy demands to the vasculature. While 
Angelo Mosso was the first to measure the relationship between neuronal firing and cerebral 
hemodynamics (18, 19), their functional association was first proposed by Roy and Sherrington 
(1). Although this view of neuronal activity-induced local increases in blood flow is widely 
accepted, recent studies have challenged the conventional picture of NVC. For example, Huo 
et al. (20) suggest that neuronal activity and blood flow are uncoupled in the frontal cortex 








Figure 1-1: A schematic representation of neurovascular coupling with its main elements. A: 
Tripartite synapse consisting of a neuronal synapse ensheathed by an astrocyte process. Two commonly 
known mechanisms of neurovascular coupling B: Direct neurovascular coupling occurs through direct 
contact between axon terminals of neurons and the blood vessel and C: Indirect neurovascular coupling 








Figure 1-2: Cross section of blood brain barrier. A: illustrates cross section at the arteriolar level where astrocytic 
endfeet interact with the smooth muscle layer. B: illustrates the cross section at the capillary level where the smooth 
muscle cell layer is absent and contractility is controlled by pericytes. 
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The neurons interact with the vascular endothelium, the anatomical substrate of blood brain 
barrier (BBB) via the interface of astrocytes, pericytes and VSMCs, forming a functional NVU. 
Each element of the NVU is described below. 
 
1.2 Neurovascular unit: functional components 
1.2.1 Neurons 
Neurons form the fundamental functional elements of the brain. They interact with each other 
through the synapse that forms the contact unit. 
The input to a neuron comprises signals coming from different nearby neurons. These are 
processed in the soma of the receiving neuron (through the dendritic end) and an output 
response is produced. The effect of input signals from other neurons is to inject currents, 
positive and negative, into the receiving neuron. The currents change the membrane voltage of 
the receiving neuron, where positive (negative) currents increase (decrease) membrane voltage.  
Such change in the membrane voltage is caused by influx and/or efflux of 
potassium/sodium/calcium ions (K+/Na+/Ca2+). Unstimulated neurons have a negative resting 
membrane potential (21, 22). When stimulated, the membrane potential rises until it reaches a 
set threshold followed by a steep rise in membrane potential. The ion gradients are restored 
back to the resting potential within 1ms and this is propagated as an action potential (AP) in 
the axon. Restoration of the ionic gradient is energetically expensive, as it requires Adenosine 
triphosphate (ATP)-dependent pumps (23, 24). Originally, the energy deficit (due to the 
activity of these pumps) was considered to be the signal communicated to the blood vessels 
(1). However, it is now known that it is neurotransmitters which act as the signal conveyed to 
the vasculature (25). Neurons are known to directly mediate NVC through neuronal nitric oxide 
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synthetase (nNOS) activations, followed by release of NO (26) or release of prostaglandins 
through cyclooxygenase (COX) 2 mediated pathways (27). 
 
1.2.2 Astrocytes 
Glial cells play many functions in the brain such as modulating synaptic activity through 
uptake of neurotransmitters and release of gliotransmitters (28, 29). Astrocytes are glial 
cells, which account for the another important cell type within the brain (than the neurons) 
(30) that are now known to occupy 15- 50% of brain volume (31). These star shaped cells 
have extremely large processes which contact approximately 10,000-100,000 synapses per 
astrocyte (32). Astrocytes perform a variety of functions. Some astrocyte processes contact 
neurons while others contact capillaries and arterioles (33, 34). Synaptic glutamate binds 
to the metabotropic and ionotropic receptors on astrocytes (35) via the tripartite synapse 
(36) leading to intracellular calcium signalling (37). This leads to activation of pathways 
releasing gliotransmitters (29) or vasoactive elements such as prostaglandins (16, 38). The 
vasoactive agents lead to calcium signalling in the ECs and hyperpolarization of VSMCs, 
causing vasodilation/vasoconstriction. On the other hand, gliotransmitters such as ATP and 
D-Serine are involved in modulating synaptic plasticity (39-41).  Astrocytes are also 
involved in spatial buffering of extracellular potassium (post neuronal depolarization) to 
maintain ionic homeostasis in extracellular matrix (42). Furthermore, they contact other 
types of glia, sensing their activations constantly. For example, myelination can be induced 
by astrocytic leukaemia inhibiting factor (LIF), released in response to ATP released by 
neurons (43).  
As a bridge between neurons and vessels, astrocytes are central to NVC (44). Glutamate 
released by active neurons has been shown to activate metabotropic glutamate receptor 
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(mGluR) 5 dependent astrocyte calcium activations (27).  This is followed by COX1 
mediated release of prostaglandins and cytochrome P450 mediated epoxyeicosatrienoids 
(EETs) release by astrocytes, leading to vasodilation (27, 45). Although various studies 
have established the importance of astrocytes, there are studies contradicting their role in 
NVC. Sun et al., (46) have shown adults mouse to lack mGluR5 thus contracting the 
astrocyte based modulation of NVC. Recent studies have questioned the contribution of 
astrocytes as the astrocyte calcium signals are very slow compared to neuronal activity (47) 
and that arterial vasodilation can occur in the absence of calcium (48).  Recent studies have 
now shown role of astrocytes at capillary (pericyte) control of NVC rather than arteriole 
(49). 
 
1.2.3 Vascular smooth muscle cells 
VSMCs regulate vessel tone. All types of vasoregulation (mechanical, chemical and humoral) 
of CBF involves VSMCs (50-54). Vasoactive agents/neuromodulators/neurotransmitters 
released by neurons and/or astrocytes act on messenger specific receptors on VSMCs causing 
arteriole dilation/constriction. For example, neurons release NO leading to hyperpolarization 
of the VSMCs and vasodilation (26, 55-57). End feet of stimulated astrocytes can alter the 
diameter of their enveloped vessels by signalling to VSMCs (58). Modest increases in 
extracellular [K+], (above physiological 10-15 mM) have been shown to increase the 
conductance of inward rectifier potassium channels causing VSMC hyperpolarization (59). 
Prostaglandins, specifically prostaglandin E2 (PGE2), relax VSMCs by binding to EP4 
receptors, decreasing the phosphorylation of myosin light chain by the activation of protein 
kinase A (58, 60). In addition to vasodilation, studies in brain slices and isolated retina have 
demonstrated vessel constriction mediated by the enzyme, cytochrome P450 4A in VSMCs 
(31). Hypoxia-associated vasoconstriction is mediated by the activation of A2A receptors on 
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VSMCs by extracellular adenosine (61). All of these effects modulate the tone of VSMCs 
causing significant changes in blood flow. Interestingly, studies have shown that VSMCs can 
indirectly affect NVC by setting the basal tone of arterioles thereby determining the magnitude 
and polarity of the vascular response to neural activity (vasoconstriction or vasodilation) (62, 
63).   
 
1.2.4 Pericytes 
Pericytes are contractile components of the NVU that wrap around the abluminal surface of 
blood vessels (in particular, capillaries). Pericytes share their precursors with VSMC (64). 
Mature pericytes and ECs share a common basement membrane which acts as a substrate for 
exchanging signals (65). Pericytes are known to aid EC development (66-68). Pericytes have 
multiple processes and cover several ECs (69, 70). The central nervous system (CNS) 
vasculature has the greatest pericyte coverage of any organ (71). The ratio of ECs to pericytes 
in the CNS is 1:1-3:1 (65, 70). Pericyte coverage is associated with the barrier properties of the 
ECs, EC turnover and blood pressure (72) and is affected in various pathologies (70, 73-75). 
Pericyte-deficient mice show higher BBB permeability (76) and recent work has suggested this 
promotes neurodegeneration (73). Pericyte dysfunction has also been observed in retinal 
diabetic neuropathy (77-79). 
Until recently it was thought that NVC was solely modulated by changes in VSMC tone (50, 
80) but studies have demonstrated the ability of pericytes to regulate blood flow at the capillary 
level (81, 82), although their role in vivo remains unresolved (83). Despite convincing 
evidence, there are a number of issues hindering the determination of pericyte function in NVC, 
in particular the lack of an agreed definition of pericytes and their detailed role in the NVU 





Since the identification of vasoactive substances such as NO (86, 87), ECs have been shown to 
play a role in vasculogenesis, regulation of vascular tone and inflammation (88, 89).  
In addition, brain ECs are the main cellular elements responsible for maintaining homeostasis 
of the NVU by secreting various trophic factors (90). Unlike peripheral ECs, cerebral 
endothelium forms tight junctions (TJs) (91, 92) to contribute to the BBB. Together with the 
adherens junctions (AJs) TJs form a selective barrier establishing a regulated communication 
between blood and brain tissue (93, 94). TJs seal the inter-endothelial cleft forming a 
continuous vessel structure (94). On the other hand, AJs initiate and maintain endothelial cell-
to-cell contact (95-97). TJs and AJ proteins provide cells with a mode to physically 
communicate with their neighbours and also play a role in intercellular signalling (93). These 
can be either transmembrane proteins (claudins, occludins, junctional adhesion molecules 
(JAM) and vascular endothelium cadherin; (Ve-Cad)) or cytoplasmic plaque proteins (cingulin, 
7H6, Rab13, ZONAB, AP-1, protein kinase C (PKC) ζ, PKCλ, heterotrimeric G protein and 
catenin family (α, β, γ, p120)) (93, 94).  
Numerous studies point to dysfunction of the endothelium in various pathologies (98-100). 
BBB disruption leads to increased paracellular permeability, entry of both inflammatory 
leukocytes and inflammatory macromolecules (101-103). Studies have shown this increases 
BBB permeability and thus various neuropathologies such as CNS inflammation, Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and epilepsy (104, 105). Pathological studies indicate 
that there are specific sets of mediators causing BBB disruption such as vascular endothelial 
growth factor (VEGF), histamines, interferons, cytokines, chemokines, free radicals, amyloid-
β, and thrombins (105-111). Microorganisms and other infective agents also breach the barrier 
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leading to “opening” of the BBB in conditions such as meningitis and encephalitis (112, 113).  
Another common mechanism of BBB disruption is by abnormal signalling pathways through 
junctional complexes (110).  
ECs have a neuroprotective role as they secrete matrix-trophic factors such as brain derived 
neurotrophic factor (BDNF) (114). They also release vasoactive substances that modulate 
vascular tone (115). These substances can be dilatory, such as NO, or constrictive, such as 
endothelin and thromboxane (116, 117). Some studies suggest ECs play a role in long range 
propagation of vasodilation during NVC (118).  
 
1.3 Neurovascular development 
1.3.1 Neurovascular congruence 
Vertebrate nervous and vascular systems are anatomically complex and follow a branched 
hierarchical morphology (119, 120). Earlier studies suggested that both systems rely heavily 
on each other for their development. Factors provided by each of the systems are necessary for 
the development of the other (121, 122). Recent research emphasizes the independency of these 
systems (123-126). It is now known that these two systems can develop independently however 
with a level of congruency due to the shared developmental mechanisms, hence termed 
neurovascular congruency (124).  
Proponents of neurovascular congruency have shown that nerves and vessels tend to follow the 
same route of development and at the same time avoid similar areas such as muscles (124). In 
vivo and in vitro studies have shown similar effects of various trophic factors on both systems, 
for example VEGF increases angiogenesis as well as axonal growth (126, 127) while 
semphorin-3A (Sem3A) inhibits capillary growth and neuronal proliferation (124, 128). 
Detailed mechanistic studies have demonstrated that nerve proliferation during development is 
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not dependent on VSMC development (124, 129). However, expression of a similar profile of 
receptors such as Neuropilin1 (NRP1) on both neurons and ECs provides evidence for shared 
mechanisms of neuronal and endothelial development (130, 131). A recent study in rodent 
whisker barrel development, demonstrates the independent development of the neuronal and 
the vascular ring with common development factors such as Sem3E and Plexin-D1 (123). The 
intimate association between the two systems is important given that the functional relation 
formed between the two becomes important for NVC. Moreover, recent evidences 
demonstrating the link between vascular anomalies and cognitive impairments further 
corroborate the importance of the association of the two systems (132, 133). It is thus a more 
generally accepted view that both systems develop independently with a similar set of trophic 
factors contributing to intricate remodelling.       
 
1.3.2 Development of functional neurovascular coupling 
Recent developmental studies have explored the nature of the hemodynamic response function 
(HRF) in postnatal, adolescents and adults in humans and rodent models (134). Various 
differences in the neurovascular responses between adults and new-borns have been suggested, 
however the characteristic pattern is not thoroughly established in rodents (135, 136).  
Functional imaging studies in rodents demonstrated a negative (inverted) BOLD response 
which was speculated to switch to a positive response with age (134, 137, 138). A recent study 
confirmed this switch in the BOLD response while also showing a local vasoconstriction in 
postnatal rats (P21) (137). Various reasons were suggested to cause the differences in HRF 
between new-borns and adults. The NVU has been shown to be incompletely developed at P7 
which could result in local or global irregular tone leading to vasoconstriction 1(134, 139, 140). 
Premature cerebral tissue is more sensitive to hypoxia due to the high metabolic demand of the 
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developing tissue which, coupled to developing cerebral autoregulation, could result in 
negative BOLD responses (141). Vessel architecture becomes more hierarchically complex 
with age which might cause a premature smaller or reverse stimulus-evoked hemodynamic 
response (142, 143). Astrocytes and pericytes have also been shown to develop during the early 
postnatal period (139, 144, 145). Other studies demonstrate spontaneous neural firing early in 
development, a possible result of developing inhibitory neuronal networks (146, 147). This is 
also supported by studies showing differences in the maturation time of the inhibitory and 
excitatory circuitries (148, 149). However, the exact age for complete maturation of the 
neurovascular response in rodents remains unclear.  
 
1.4  Hemoneural hypothesis of vascular feedback 
NVC suggests a unidirectional communication between neurons and vessels via the interface 
of astrocytes (described above).  In 2008, Moore and Cao (150) proposed the ‘hemoneural 
hypothesis’, which suggests the vasculature can modulate neuronal activity and that NVC is 
thus not unidirectional.  
The mechanisms by which the vasculature can influence neural activity have been proposed to 
be either direct or indirect (via astrocytes). Direct vasculo-to-neural regulation could be 
mediated via diffusible vascular derived NO through the BBB (151), hyperemia-induced 
activation of neuronal mechanosensitive ion channels, or temperature-dependent 
activation/inactivation of neuronal activity. Indirect or astrocyte-mediated hemo-to-neuronal 
signalling could occur on a second-to-tens of seconds time scale compared to millisecond-to-
second time scale for the direct pathway. Astrocyte mediated neuronal activity modulation has 
been well studied through the effect of astrocyte-released gliotransmitters such as glutamate, 
ATP and D-serine (152-154). Furthermore, it is known that vascular derived NO can lead to 
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calcium oscillations in astrocytes followed by release of glutamate and ATP (155). These 
observations suggest astrocytes are plausible players in ‘hemoneural coupling.’  Another 
potential mechanism suggested in the hemoneural hypothesis was through transduction of 
mechanical changes in the vasculature via mechanosensitive channels (156-158). The 
proximity of astrocyte processes to the vasculature make them ideal for sensing mechanical 
changes in the vasculature (159, 160). The role of astrocyte vallinoid transient receptor 
potential (TRPV4) channels in mediating vasodilation has been previously described (161). A 
recent in vitro study emphasized the role of cerebral vasculature in adjusting neuronal resting 
activity through the activation of TRPV4 channels on the astrocytes (160).  
 
1.5  Neurovascular dysfunction in various neurological and vascular disorders 
Neurovascular dysfunction broadly encompasses anomalies in both NVC and improper 
functioning of the NVU. fMRI-BOLD studies show that impaired brain vascularization is a 
predictor of dementia (162).  
Various pathological states are associated with impaired NVC known as neurovascular 
‘uncoupling’ (163). Clinical studies have shown that astrocytoma induced neurovascular 
uncoupling causes speech arrest in patients (164). Hypoxia studies in rodent models 
demonstrate impaired CBF during forepaw stimulation (165).  
The conventional hypothesis of AD pathogenesis emphasizes on amyloid-β accumulation as 
the initiation various pathways leading to tau pathology and neuronal dysfunction. Various 
experimental studies over more than a decade have shown cerebral blood flow is impaired in 
AD which may be due to impaired NVC (166, 167). Thus, an alternative hypothesis was 
suggested (two-hit vascular hypothesis of AD) proposing damaged brain microcirculation 
initiating a non-amyloidogenic pathway of vascular mediated neuronal dysfunction (hit one) 
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caused by dysfunctional BBB (168). Impaired amyloid-β clearance and increased amyloid-β 
production have been shown to be an effect of BBB disruption thus causing an accumulation 
of amyloid-β (hit two) in the brain (133, 168-171).  Thus, the alternative hypothesis suggests 
tau pathology in AD to be an outcome of vascular dysfunction which could be associated of 
impaired NVC (168). Disruption of NVC in mice is associated with impaired spatial and 
recognition memory alongside motor incoordination (172). Amongst the various reasons 
attributed to these impairments, inflammation and infiltration of leukocytes are major factors 
(169). Recent studies have shown that amyloid deposition in AD affects VSMC contractility 
(173), Astrocyte degeneration has also been suggested to be involved in the pathogenesis of 
AD (174).  While there are various studies discussing neurovascular dysfunction in AD, few 
studies have shown NVC deficits in PD. Using simultaneous Electroencephalogram (EEG)-
Doppler technique, a recent clinical study has shown neurovascular uncoupling in PD patients 
(175). Gait dysfunctions as seen in PD are also observed in mouse models with cerebrovascular 
dysfunctions (176, 177). Genetic studies have shown various genes to be mutated in familial 
PD such as phosphatase and tensin homolog (PTEN) induced putative kinase 1(PINK1, (178)), 
various domains of α-synuclein (SCNA, (179)), leucine-rich repeat kinase 2(LRRK1, (180)), 
parkin (181), protein deglycase (DJ-1, (182)), lysosomal membrane protein, (ATP13A2, (183)) 
and guanine triphosphate (GTP)-hydrolase (GCH1, (184)). Recent clinical studies have shown 
GCH1 to be one of the major risk factors for Dopa-responsive dystonia (DRD) and PD (185). 
This gene will be a focus of some of my data in subsequent chapters. 
Demographic studies suggest vascular disorders are one of the central risk factors in 
neurological conditions such as stroke and dementia. Conversely, AD and PD lead to a 
cholinergic deficit which impairs NVC (186). Recent findings also demonstrate a link between 
cerebral small vessel disease and cognitive impairment (187). 
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Hyperglycemia is a major component of type II diabetes mellitus (T2DM), and various studies 
elucidate the effect of hyperglycemia on components of the NVU morphologically and 
anatomically in either cerebral or retinal models such as streptozotocin induction of diabetes in 
mammalian (188, 189) and other approaches in non-mammalian systems (190, 191). The retina 
has been the most used system since retinopathy is a prominent complication of T2DM (192, 
193).  
  
1.6 Effect of hyperglycaemia on components of NVU 
1.6.1 The effect of hyperglycaemia on the endothelium 
EC dysfunction occurs in diabetes prior to macro and microvascular complications such as 
nephropathy, retinopathy, atherosclerosis and coronary heart disease (194). EC possess 
remarkable phenotypic plasticity in response to physiological variations (195). Normal blood 
glucose ranges from 3.6-5.8 mmol/l which is tightly regulated by metabolic homeostasis (196). 
In this range ECs are in a ‘quiescent’ state (196, 197). Under hyperglycemic condition (>10 
mmol/l) ECs lose their quiescence and acquire new phenotypes also termed ‘endothelial cell 
dysfunction’ (196). Impaired endothelial function is characterized by features such as a deficit 
in the bioavailability of NO, reduced endothelial-mediated vasorelaxation, increased 
expression of adhesion molecules and inflammatory genes, overproduction of reactive oxygen 
and nitric species (ROS and RNS) and increased BBB permeability (198, 199). These events 
are speculated to be followed by ‘endothelial senescence’ leading to microvascular 
complications (200). Retinal studies in mouse have shown upregulation of FOXO1 
transcription factor which is known to promote inducible NOS (iNOS) dependent peroxynitrite 
generation leading to low density lipoprotein (LDL) oxidation and endothelial NOS (eNOS) 
dysfunction (201). Corroborating this, other studies have confirmed a link between FOXO1 
upregulation and EC loss in the retina of diabetic rats (201, 202). Recent data have additionally 
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shown activation of JAK2/STAT3 pathway and of VEGF and of NADP(H) oxidase followed 
by ROS generation under hyperglycemia (202).  
 
1.6.2 The effect of hyperglycemia on neurons 
Various studies have associated hyperglycemia with cognitive impairments (203). The effects 
of hyperglycemia on the components of the NVU as described above results in 
neuroinflammation (204, 205). Psychophysical studies involving tests such as contrast 
sensitivity, color vision and focal electroretinography (ERG) have shown significant 
differences in diabetic individuals (206). It is unclear if these neurosensory deficits occur prior 
to identifiable vascular complications.  
At the neuronal level, cell viability studies with PC12 cell cultures have shown increased 
neurotoxicity with high glucose conditions similar to Parkinson’s studies with PC12 cell lines 
(207). Glutamate is one of the most important excitatory neurotransmitters in the brain and 
increased levels of extracellular glutamate are observed in diabetic retina (208). Adenosine, 
another important molecule with respect to neurotransmission and gliotransmission has the 
capability to inhibit the extracellular accumulation of the excitatory amino acids. Studies have 
shown that adenosine signalling is affected under high glucose conditions with downregulation 
of A1 adenosine receptor and upregulation of A2 adenosine receptor (209). Thus ameliorating 
the adenosine system could be a possible way to prevent neuropathy associated with diabetes.  
In addition to the excitotoxic effects and abnormalities in the neurotransmission system, high 




1.6.3 The effect of hyperglycemia on astrocytes 
Astrocytes or astroglial cells are critically placed between the neurons and blood vessels. Given 
their role in the NVU and NVC (as described earlier), understanding this role may help our 
understanding of diabetic neuro and vasculopathy. Retinal studies with streptozotocin-induced 
hyperglycemia in rodents have shown that within 4 weeks, there is a significant vascular 
leakage and the number of astrocytes reduces alongside macroglial abnormalities (211, 212). 
Studies have speculated that these multiple insults to the glial system lead to hyperplasia of the 
Muller cells (retinal analog of astrocytes) followed by an increase in glial fibrilliary acidic 
protein (GFAP) (211). 
Recent studies have shown changes in the morphology of astrocytes in the forebrain of induced 
ischemic rats (213). These studies show astrocyte endfoot retraction from the cerebral blood 
vessel walls, providing evidence for astrocyte-related detrimental effects of ischemia observed 
during hyperglycemia (213). Another feature of hyperglycemia is astroglial acidosis wherein 
the role of astrocytes in maintaining an alkaline pH is compromised due to inhibition of 
transport of bicarbonate (HCO3-) ions (214, 215). While acidosis is a prominent feature of the 
ischaemic brain, it has been recently attributed to astrocyte malfunction of spatial buffering 
(214, 215). Apart from maintaining pH balance, another important role of astrocytes is to 
maintain ionic balance by regulating extracellular ionic concentrations. Firing neurons release 
potassium ions in the extracellular space which are taken up by astrocytes via inward rectifying 
potassium (Kir) receptors, (216). Failing this uptake, the membrane potential of the surrounding 
neurons would stay in the depolarized condition changing the ions homeostasis in the neurons. 
In vitro studies with cultured astrocytes demonstrate that high glucose reduces expression of 
Kir4.1 by 50% (216, 217). In addition, astrocytic glutamate clearance is also impaired under 
high glucose conditions making neurons extremely susceptible to depolarization, a possible 




1.6.4 The effect of hyperglycemia on microglial cells 
Microglia are resident immune cells of the CNS and are derived from myeloid progenitors that 
migrate to the periphery during late embryonic life (219). They use phagocytic and cytotoxic 
mechanisms against pathogens and other substances, similar to macrophages (219, 220). They 
can be either neuroprotective or toxic depending on the brain state (220). Several studies have 
characterized the resting state morphology of microglial cells (221). They are shown to have 
long and diffused processes under basal state which are transformed during inflammation to a 
hypertrophic and proliferative state with less ramified morphology (221). Under inflammatory 
conditions, microglial activation is followed by activation of the macroglia such as astrocytes 
as well (222). However, few studies have shown the direct relation between microglial and 
macroglial activation. On the contrary retinal studies in rodent have speculated the nature of 
activation of microglial cells to be either from the damaged/injured neural parenchyma and/or 
activated macroglial cells (223). Studies have also suggested that during early diabetes 
microglial cells closely approach the axons and ganglion cells making them more vulnerable 
to activated state (223).  
Studies with postnatal P2-6-day old rat pups have shown hyperglycemia to be characterized by 
significant CCL2 chemokine activation at P6 alongside increases in the total number of 
macrophages/microglial cells in the inner nuclear layers of the retina (224, 225).  
 
1.6.5 The effect of hyperglycemia on pericytes 
Pericytes are the contractile machinery of the microvasculature and form a crucial unit of the 
NVU (as described earlier). Various pathological studies have implicated anomalies in the 
pericytes to accompany microvasculopathies (75) related to cardiovascular disorders (226). 
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Clinical studies have shown fewer pericytes (possibly due to increased migration), termed 
‘pericyte dropout’, in patients with diabetic retinopathy (77, 79). Research in platelet derived 
growth factor receptor β (PDGFRβ) null (-/-) mice have shown a reduction (50%) in pericytes 
similar to that in diabetic mice (40%) (73, 227). This reduction correlates with more acellular 
capillaries that could induce angiogenic defects and increased vessel permeability (228, 229). 
Interestingly, a few studies have suggested that these pericyte alterations occur prior to the 
endothelial dysfunction observed under various microangiopathies (74).  
Various cell signalling pathways in pericytes are affected by hyperglycemia. Human retina 
studies have shown increases in methylglyoxal and α-oxalodehyde in pericytes exposed to 
hyperglycemia (230). These increases have been attributed to defective glyoxylase-I function 
in the pericytes which has a protective role (230). In addition, studies with mouse retina have 
shown loss of platelet derived growth factor (PDGF) mediated survival mechanisms in 
pericytes attributed to activation of PKC-α and p38 alpha mitogen activated protein kinase 
(MAPK) which overexpresses a protein tyrosine phosphatase called Src-homology 2 domain 
containing phosphatase (SHP-1) (231). This leads to downstream phosphorylation of the PDGF 
receptor, possibly leading to apoptosis underlying the vascular complications of 
hyperglycemia.  
 
1.7 The effect of hyperglycemia on neurovascular coupling  
Our brain consumes around 20% of the cardiac output and thus consumes a relatively higher 
amount of glucose and oxygen compared to any other organ in the body. This is mainly 
attributed to the neurons not having their own energy storage system in form of glycogen 
reserves.  The BBB and its components maintain the requisite resistance for particles and/or 
substances entering the bloodstream. Glucose is the main energy molecule in the brain although 
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there are controversial studies suggesting lactate can also act as an energy source for neurons 
(232, 233). Although the extracellular matrix surrounding the neurons maintains a glucose 
concentration of 2-4 µmol/g (234), glucose can pass through the selectively permeable BBB 
formed by astrocytes and ECs (235). Glucose transport from the bloodstream is mainly aided 
by glucose transporters (GLUT)1-5 (236, 237). Dysfunction of glucose transport may lead to 
hypo or hyperglycemia in the brain; hyperglycemia being the fundamental phenotype of 
diabetes (238). 
Diabetes mellitus and its related vascular complications are one of the leading causes of death 
in the western world. Diabetes leads to a range of effects, one of the most crucial being 
cognitive impairment (239, 240). This could be due to defects in the NVU such as endothelial 
senescence, astrocyte disruption and neuroinflammation leading to impairment of NVC. Other 
studies have shown association of diabetic retinopathy with microvascular dysfunction and 
NVC (241, 242). Acute streptozotocin injection causes a reduction in hyperaemia in rodent 
models (243). Furthermore, mechanistic studies have described the role of protein kinase C 
(PKC) and modulation of BKCa (calcium dependent potassium channels) and Kir channels in 
diabetes (244). However, it is unclear whether impaired NVC observed as a result of diabetes 
makes the brain more prone to dementia and related cognitive defects.  
 
1.8 The pathological consequence of hyperglycemia as gestational diabetes 
Gestational diabetes mellitus (GDM) is a common phenomenon associated with 2-9% 
pregnancies.  Women with GDM have an increased risk of adverse perinatal outcomes 
including macrosomia, early induction of labour and caesarean section (245). GDM increases 
the risk of the offspring to develop cardiovascular disease in later life (246, 247). GDM is thus 
associated with ill health outcomes in both the mother and the offspring (248). Given that 
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hyperglycemia affects neurovascular function and possibly cognition (as discussed earlier), 
GDM might cause cognitive defects in the later life of offspring.  
 
1.9 Possible role of vascular feedback in hyperglycemia (role of TRPV4) 
The transient receptor potential (TRP) family of genes comprises canonical TRPC, melastatin 
(TRPM), polycystin (TRPP) and vallinoid (TRPV) (249, 250). The TRPV subfamily is 
composed of various homologues which play a role in nociception, mechano-sensing, 
osmolarity-sensing and thermosensing (251, 252).  All are Ca2+ selective channels gated by 
capsaicin, acidosis and endogenous ligands such as anandamide (252).  
Emerging evidence suggests that TRP channels play a role in neuronal Ca2+ signalling (253). 
TRPV4 channels are known to be expressed on astrocytes, neurons and ECs (253-255). 
Interestingly studies have shown that TRPV4 in ECs can regulate eNOS (256) and that there 
exists a feedback loop from endothelial NOS to TRPV4 to modulate TRPV4 based Ca2+ 
signalling (257). Recent studies have shown the presence of TRPV4 on the endfeet of cortical 
astrocytes causing changes in the intracellular astrocyte calcium and therefore modulating the 
vascular tone and contributing to NVC (157, 258).  
Clinical and experimental studies have shown TRPV4 dysfunction to be associated with 
hyperglycemia and diabetes (31). Studies on rodent retinal microvasculature have described 
retinopathy induced by streptozotocin injection to be associated with downregulation of 
TRPV4 in the ECs and thereby reduction in retinal endothelial Ca2+ signalling (259). TRPV4 
mutations are linked to neuropathies and play a role in inflammation via its interaction with 
eNOS (260). TRPV4 is also associated with axonal degeneration (261) attributed to TRPV4 
associated neuroglial swelling and inflammatory signalling (262).  However, as the link 
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between neurodegeneration and dysfunctional NVC is unclear, the contribution of TRPV4 
dysfunction to NVC and neurodegenerative diseases is not precisely known.  
 
1.10 Imaging paradigms for investigating functional neurovascular coupling 
There are several methods for studying NVC in mammalian models with a range of spatial and 
temporal resolutions. Frequently used techniques include  minimally invasive modalities such 
as fMRI-BOLD (263), laser speckle contrast imaging (264), photoacoustic microscopy, near 
infrared spectroscopy (265), 2D optical intrinsic spectroscopy (266) and invasive modalities 
such as voltage sensitive dye imaging using multi-photon imaging (267). Although requiring 
chronic surgery, there is now an increasing use of invasive methodologies for investigating 
NVC. This is due to several reasons such as: better spatio-temporal resolution compared with 
non-invasive methodologies, and blood flow measures (such as BOLD) being surrogate 
measures of the neuronal activity rather than directly reflecting neuronal activity (268). 
Furthermore, lightsheet microscopy is also being used to image GCaMP dynamics, and NVU 
in awake mouse preparations (269). Lightsheet microscopy, due to its high spatial and temporal 
dynamics, has been proposed to be better than multiphoton imaging due to less photo bleaching 
(270, 271). 
 
1.11 The use of zebrafish as a model for studying disease and neuroscience  
There are various animal models used in neuroscience; primate models such as monkeys, 
rodent models such as mice, rats, other non-mammalian models include zebrafish, Drosophila 
and C. elegans. While primate models are important for cognitive studies, rodent models 
dominate experimental neurophysiology. However, non-mammalian models such as zebrafish 
are increasingly being used (272, 273). The first use of zebrafish models dates to the 1950s and 
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since then they have become a common model for developmental biology and genetics. A range 
of genetic and imaging technologies have been developed allowing application of the model to 
neurophysiology, biomedical research and ethology (274). With the advent of genome 
sequencing their use in biology and medicine has increased (275), including in the study of 
various disorders such as PD, AD, Huntington’s disease and psychiatric diseases (276-278).  
Their tractable genome gives the advantage of various mutagenesis and functional genomic 
studies (279). In addition, their physical properties such as transparency and short life span 
makes them amenable to many research questions. 
1.11.1 Zebrafish nervous system 
With development in imaging technologies, the use of zebrafish in neuroscience has increased 
(280). Zebrafish provide an intermediate level of complexity between mammals and 
invertebrates. Current studies employ both adult and larval zebrafish to understand brain 
physiology (280). Due to ease of genetic manipulation and novel microscopy techniques, a 
range of transgenic models have been generated to study various aspects of neuronal activity 
and function such as a quadruple transgenic line labelling four different retinal cell types (281, 
282). With the advent of genetically encoded calcium reporters, any neuronal cell type 
responses can be characterized and studied in response to stimulus (283). In addition, studies 
characterizing various other neuronal subtypes have shown similar brain stratification in 
zebrafish as in mammals. While it is well known that the zebrafish have distinct forebrain 
(284)have also shown the dorsal telencephalic region (Dm) to be the anatomical homologue of 
the mammalian amygdala (285, 286). Decision making in zebrafish involves the dorsal nucleus 
of the ventral telencephalic area (Vd), the zebrafish homolog of the mammalian striatum (285). 
The zebrafish visual circuitry is composed of retinal ganglion cells, amacrine cells, bipolar 
cells similar to other vertebrates (287, 288). The main system of the visual processing circuitry 
is the seven layered optic tectum (teO) which is analogous to the visual cortex in 
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rodents/humans. Furthermore, the architecture of zebrafish brain systems such as retina, 
olfactory bulb, cerebellum and spinal cord is similar to other vertebrates (288). Retinal inputs 
are carried by the retinal ganglion cells (RGCs) to ten different anatomical areas known as 
arborisation fields (AF1-10) (289). These are homologous to parts of the human visual circuitry 
(290). For example, AF1 is homologous to the suprachiasmatic nuclei and AF9 to the pretectal 
nucleus of the optic tract. AF10, the teO, is a homologue of the mammalian superior colliculus 
(SC) (290). However, the architecture of teO is much more complex than that of the SC and 
comprises seven layers with unique cell types (290, 291). It is speculated that one of the main 
reasons for such complexity is that teO performs the visual processing performed by the 
neocortex in mammals (289). TeO is accessible to electrophysiology, optical imaging, laser 
ablation and control of neuronal activity by optogenetic effectors due to its position on the 
surface of the brain. Studies suggest that the teO is primarily involved in tasks requiring a map 
of the visual space such as phototaxis, the approach of prey, or avoiding obstacles (292). A 
functional teO is necessary for assessing illumination, reflexes to moving stimuli such as 
optomotor or optokinetic responses, visual background adaptation, dorsal light reflexes or 
adjustment to the circadian rhythm (292). Anatomically the teO comprises two regions, a deep 
cell body layer, the stratum ventriculare (SPV), and a superficial neuropil area consisting of 
dendrites and axons from tectal neurons, some tectal interneurons, and afferent axons arriving 
at the tectum from the retina (293, 294). At the cellular level, responses in the tectum itself are 
variable and heterogeneous. Calcium imaging studies show that some neurons respond to 
looming stimuli, some to moving edges, others to objects within a certain size range (293). 
Different object positions are mapped onto different regions in the tectum. Objects in the 
forward visual field are mapped onto anterior tectum and those behind the fish to posterior 
tectum (294, 295). Similarly, objects in the upper and lower visual field activate dorsal and 
ventral tectum, respectively (294, 295). Furthermore, there is hard wired direction sensitivity 
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in the zebrafish teO (295, 296). The information from the tectum is received by premotor areas 
in the midbrain/hindbrain (reticular formation) and passed on by hindbrain target areas to spinal 
cord to elicit coordinated motor responses (290, 291).  
Neuronal circuit mapping studies have established that the afferents from the teO to Vd and 
Dm (290, 291). Recent studies have established zebrafish necessitate light/dark choice 
selection by sending information about the ambient light conditions (297). Hence the 
conventional light/dark test used for testing anxiety in zebrafish (297) could be considered as 
a cognitive test of amygdala/striatum function or connectivity between TeO and Vd/Dm. Larval 
zebrafish prefer light to dark while the adult form prefers dark to light (298, 299). 
Using high speed cameras along with high resolution microscopy, various studies have 
established the existence of behaviours such as escape, hunting, shoaling, association, sleep 
and learning in larval zebrafish (300-302). Another well characterized behaviour in zebrafish 
is optokinetic reflex established in 5 dpf old zebrafish larva (303). Zebrafish are also known to 
have complex swimming patterns and tail movements, all of which are developed from 4-5 dpf 
alongside the development of the visual system (304). These swimming bouts have been 
compared to motion trajectories observed and computationally characterized in mammalian 
models such as rodents (305). However, attempts to model and characterize behaviours using 
machine learning approaches have only started to be pursued recently. An interesting object 
familiarity recognition based on saccadic movement has also been recently described using 10 
dpf zebrafish (306). Functionally, zebrafish exhibit complex conditioning such as reward and 
fear based learning (307). The larval zebrafish is also capable of responding to aversive stimuli 
such as electric shock (307). Imaging studies demonstrate the presence of a core network area 
such as in locus coerulus (LC) which responds to multiple stimuli (308). The same study also 
found a well-organized activity map during complex behaviours such as prey hunting (308, 
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309). Given this repertoire of behaviours, larval zebrafish have gained popularity in functional 
neural circuit research.  
 
1.11.2 Zebrafish glial system 
Both adult and larval zebrafish brains contain radial glial cells, microglia, niched ependymal 
cells and oligodendrocytes (310-312). The presence of typical stellate astrocytes in zebrafish 
brain is unclear. There are tandem arrays of stellate cells (astrocytes) in the spinal cord 
contacting the spinal veins with their end feet (313). However, no studies have shown the 
presence of stellate astrocyte-like cells in the central nervous system of zebrafish.  Recent 
studies have shown radial glial cells in zebrafish brain to possess astrocyte-like physiology in 
terms of expression of various astrocyte specific receptors (314, 315). Immunostaining has 
established the presence of tight junction proteins; zona occludins- 1 (ZO-1), glutamine 
synthase (GS), claudin-5a and GFAP in radial glial cells of adult zebrafish (316, 317). Larval 
zebrafish radial glial cells express the above proteins from 3 dpf, suggesting the BBB to be 
formed from this stage (318, 319). Zebrafish glial cells have been shown to express aquaporin 
channel 4, a characteristic of mammalian astrocytes (315), thus getting the name ‘astroglial 
cells.’ Radial glial cell ablation studies have now established their importance in venous 
vascular sprouting in the trunk (319). This study also suggested a differential influence of radial 
glial cell on cerebral and trunk vascular development. On similar lines, recent research has 
demonstrated the presence of glutamate transporter, Glt1, on radial glial cells suggesting their 
role in synaptic modulation and recycling similar to astrocytes (320). While a typical 
regenerative function of radial glial cell is well established in both larval and adult forms, their 




1.11.3 Zebrafish vascular system 
Zebrafish are an established model to study vascular development due to advantages such as 
optical clarity and rapid development. Due to their size, zebrafish embryos obtain enough 
oxygen by diffusion for survival and development for several dpf in the absence of blood flow 
(321). 
The basic layout of the circulatory system is conserved between fish and other vertebrates such 
as mammals (321), and blood vessel patterning in developing teleosts is also similar (321). 
Formation of vasculature involves vasculogenesis and angiogenesis (321, 322). 
Vasculogenesis starts ~12 hours post fertilization (hpf) and is the process of formation of new 
blood vessels without pre-existing vessels. This establishes the major axial vessels and is 
followed by angiogenesis such as vessel sprouting from the dorsal aorta (DA) at ~22 hpf (322). 
Each angiogenic sprout comprises several ECs that migrate dorsally anastomosing to form a 
vascular network (322, 323).  This is remodelled following onset of circulation at ~1-1.5 dpf 
(321).  In the midbrain, the vasculature undergoes stereotypic pruning events driven by blood 
flow between 3-8 dpf (321, 324). This is also marked by formation of the blood brain barrier 
by interactions between ECs, pericytes, astrocytes and neurons (325, 326). 
 
1.12 Computational approaches to modelling brain function 
1.12.1 Computational models of the neurovascular unit 
 
NVC is often examined by functional imaging studies which measure the hemodynamic 
responses to neural activity. Although fMRI signals are informative, it is not straightforward 
to precisely predict the underlying neural activations from the BOLD response. The main 
challenge involved in accurate interpretation of fMRI signals is the incomplete understanding 
of NVC mechanisms. There is need for computational models to improve our understanding 
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of NVC. There have been various modelling efforts but these are restricted to modelling 
neuron-vessel (327, 328) and neuron-glia interactions (327, 329, 330). Only a small number of 
studies model neuron-glia-vessel interactions (331-334).  
Neuron-glia models have been recently emerging in keeping with the growing importance of 
glial cells in modulating neuronal function. Kaeger et al. (335) modelled the buffering role of 
glial cells using Hodgkin Huxley (HH) conductance models (336) for neurons and first order 
kinetic system for glial potassium buffering.  
Neuron-vessel models have mostly aimed to understand functional imaging signals (BOLD) 
and their dependence on neuronal metabolism. The Aubert and Costalat model was amongst 
the first to describe a mathematical relation between stimulation evoked neuronal activity and 
hemodynamic response (327). A detailed vascular network model was later proposed that 
successfully reproduced the BOLD response using a simple stimulus induced neuronal 
response (328). This model also predicted baseline blood pressure and haemoglobin oxygen 
saturation close to that observed in rodents. Although elegant, this model did not account for 
complex features such as surround negativity of the BOLD response.  
Neuron-glia-vessel models have recently been proposed with both the aim of understanding 
BOLD responses (328, 337) and investigating NVC mechanisms (331, 334). Although most of 
these models have been very detailed with several differential equations, recent simple low 
dimensional models recapitulate the findings of these more detailed models (333). Such simple 
computational models incorporate essential aspects of neuron, glial and vessel compartments 
and are extremely convenient to model neurovascular networks, predicting the effect of various 
pathologies on local field potential (LFP) and vascular network activity.  
There is a need to develop such models to understand the basis of neurovascular uncoupling 
observed in various neurodegenerative and cardiovascular disorders. The feature of scalability 
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to networks is important to investigate disease phenotypes (such as those measurable by EEG 
and BOLD) which are a result of network interactions between neurons or glia or blood vessels. 
Another interesting application of developing computational models of the NVU is to 
investigate the role of the vascular system in modulating neuronal and glial activity. At a 
systems level, the neuronal system is coupled to the vascular system which makes it difficult 
to study either in isolation with current experimental technologies. Hence, having a plausible 
computational model of NVC grounded in experimental reality would help understand the 
impact of the vascular system on neuronal excitability. 
Vascular tone is suggested to influence astrocyte and neuronal activation as suggested by the 
hemoneural hypothesis. Recent studies (338), have attempted to model the influence of 
vascular feedback on astrocytes through TRPV4 channels. However, the effect of such blood 
vessel-astrocyte interaction on neuronal excitability (339) has not been examined.  
 
1.12.2 Modelling of synaptic plasticity 
 
A fascinating feature of the brain is its ability to modify neuronal circuitry depending on 
activity known as brain plasticity. This governs learning in neuronal networks and is necessary 
to form memory representations. 
Several studies have proposed various mechanisms of synaptic plasticity. There are mainly two 
forms of induction of synaptic plasticity; short term plasticity (STP) and long term plasticity 
(LTP).  
STP is the first form of synaptic plasticity discovered in Aplysia (340). It is in the order of 
shorter time scales such as from milliseconds to several minutes. It is generally associated with 
short term adaptation of sensory stimulations and could be also generated by short bursts of 
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neuronal activity. Studies have shown that STP causes a change in the probability of 
neurotransmitter release (341). There are various mechanisms proposed for STP such as paired 
pulse facilitation and depression of synapses (342), modulation of neurotransmission by 
changing occupancy of presynaptic receptors (343) and glia driven clearance and release of 
modulators such as glutamate and ATP (344).   
LTP is on the order of hours and is responsible for long term modulation of synaptic strength 
(345). LTP is a common mechanism adopted by all types of synapses in the brain (346) and 
has been comprehensively studied in the hippocampus in form of N-methyl D-aspartate 
receptor (NMDAR) based facilitation/depression of synapses. Pioneers of the field such as 
Ramon y Cajal and Donald Hebbs proposed the association between memories formed in the 
brain and synaptic modification based strengthening of neuronal connections (347). In this 
framework, synaptic strength (also called synaptic weight) is governed by temporal 
correlations between pre- and post-synaptic neuronal activity (348). Various studies have 
proposed the importance of this temporal correlation within a defined ‘critical window’ for 
spike timing which are on the order of tens of milliseconds (349). This is commonly referred 
to as spike time dependent plasticity (STDP) and experimental data have established the time 
scale of the critical window by correlating the change in the evoked potentials (synaptic 
strength) after repetitive retinal stimulation (Figure 2-4). STDP is now widely implemented in 
computational modelling of neuronal networks to show learning and memory in spiking 
neuronal networks (350). In this thesis, I have proposed a computational model demonstrating 






Figure 2-3: The Critical window for STDP established from experiments by Zhang et al. (345) 





1.13 Aims and hypotheses 
In this thesis, I aimed to develop a zebrafish model of NVC using novel compound transgenics, 
lightsheet microscopy and custom made analytical computational tools in MATLAB. Using 
this, I tested the following hypotheses: 
1. NVC in zebrafish is similar to mammals in spatiotemporal scale and is mediated by NO 
and COX (Chapter 3). 
2. Hyperglycemia impairs NVC through its impact on various cells forming the functional 
NVU (Chapter 4). 
3. Since NO availability is affected in hyperglycemia and is important for NVC, 
augmenting NO will ameliorate hyperglycemic neurovascular deficits (Chapter 4). 
4. gch1 mutant zebrafish will display alterations in NVC similar to that observed under 
hyperglycemia (Chapter 5). 
5. It is possible to generate a computational model of neuron-astrocyte-vessel interactions 
with NO dynamics and vessel-to-neuron feedback to explain the observation of 
hyperglycemia induced neurovascular impairment and predict possible effects on 




2 Materials and methods 
 
2.1  Zebrafish maintenance and manipulation 
All zebrafish maintenance and manipulation were carried out in accordance with the Animals 
(Scientific Procedures) Act (ASPA), 1986, United Kingdom and were performed under Home 
office project licence 70/8588 held by Prof. Tim Chico. All experiments are reported in 
compliance with ARRIVE (Animal Research: Reporting in vivo experiments) guidelines (351).  
2.1.1 Zebrafish husbandry 
 
Adult zebrafish were housed in monitored aquariums with 14 hour (h) light/10 h dark cycle, at 
28 °C with regular feeding with protein rich mix of Artemia and flake food.  The tanks of each 
strain were maintained at 0.25l/water per fish tank.  
2.1.2 Zebrafish embryo collection and maintenance 
 
Zebrafish embryos were obtained by in-crossing adults unless specified. Eggs were kept in E3 
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 10
-5% Methylene 
Blue) at 28 °C in an incubator up until 5.2 dpf. Post 5.2 dpf, embryos require external feeding 
and are therefore protected (Animal scientific procedures act, ASPA), and maintained by the 
Named Animal Care and Welfare officer (NAWCO) with proper feeding (Gemma Micro 75 
Fry powder) and regular changing of E3 media (without Methylene blue). Embryos were kept 
in a 50 ml petridish in numbers not exceeding 60 per plate from 1-10 dpf.  
 
2.1.3 Zebrafish transgenic lines for visualizing neurovascular unit 
 
I have combined various transgenics (Tg) including neuronal, erythrocyte, endothelial, glial 




2.1.4 Zebrafish euthanasia and confirmation of death 
 
Post 5.2 dpf, embryos undergo Schedule I procedures involving treatment with 4.2% (v/v) 
tricaine mesylate (MS222) in for 20 minutes, followed by confirmation of death. Standard 
methods used for confirmation of death include permanent cessation of blood flow or 










 Table 2-1: Table of various transgenic reporter lines used to investigate neurovascular function. 
  







nbt:GCaMP3 Pan- neuronal Improved form of GCaMP 
with higher signal to noise 
(SNR) ratio (352) (353, 
354), specific to neurons in 
zebrafish expressing n-beta 
tubulin (nbt) (355) 
GFP (488 nm) Dr. Vincent Cunliffe 








Promoter is specific for 
kinase inset domain 
receptor like (kdrl)(356) to 
visualize developing 
vascular morphology 
mcherry (561 nm) Siekmann group, 






klf2: GFP Endothelial 
transcription factor 
reporter 
Kruppel like factor 2a 
(klf2a) is a zinc finger 
transcription factor that 
transduces physical forces 





GFP (488 nm) Dr. Caroline Gray 
University of 
Sheffield 
claudin5: GFP Endothelial 
junctional reporter 
Claudin5a determines the 
paracellular permeability of 
tight junctions the BBB and 
neuroepithelial-ventricular 
barrier (326) 
GFP (488 nm) Dr. Simon Andrew 
Johnston, University 
of Sheffield 





calcium reporter driven by 
friend leukaemia 
integration transcription 
factor 1(fli1) promoter 
GFP (488 nm) Dr. Aylin Metzner, 
Dr. Aaron Savage 




gata1: DsRed Erythrocyte 
reporter 
 gata1 (encoding for GATA 
binding protein) promoter 
drives the expression of 
DsRed in erythropoetic 
cells, thus marking all 
mature erythrocytes (357) 
DsRed (561 nm) ZIRC (Zebrafish 
International Resource 
Centre, Oregon, USA) 




GFAP: iGluSnFr Glial cell 
membrane reporter 
Expressed on the surface of 
the glial cells in the central 
nervous system and marks 
the glutamate uptake by the 










Mural cell reporter Expressed in all mural cells 
(VSMC, pericytes) with 
smooth muscle actin 
(unpublished) 





2.2  Lightsheet microscopy of live zebrafish embryos 
Lightsheet fluorescent microscopy (LSFM) was used for acquiring two dimensional time series 
(2D+t) with simultaneous visual stimulation, or for acquiring 3D z stacks for analysis of 
cerebrovascular anatomy. For single z plane imaging, a region of 800 x 600 pixels was chosen, 
and for 3D imaging the same X-Y dimensions were used with a depth of 90 planes in Z 
dimension. Each pixel in X-Y had a scaling factor of 0.6 µm and each of the z plane thickness 
was 1 µm.   
A compound transgenic, Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:Dsred) was generated 
using the transgenics detailed in Table 2-1 for quantifying NVC and for analysing 
cerebrovascular patterning.  
LSFM was performed on 4-9 dpf embryos on a Zeiss Lightsheet Z.1 microscope (Carl Zeiss 
®). The embryo was embedded in 1% or 3.5% low melting agarose (Sigma ®), and loaded in 
a glass capillary (with inner diameter ~ 1mm). 1% agarose was used for embryos minimally 
anaesthetised with MS222 before imaging, whereas 3.5% agarose was used for un-
anaesthetised embryos to restrict movement of the embryo while imaging. Embryos were 
suspended vertically in a chamber filled with E3. Physiological conditions were maintained 
using a Peltier based heating and cooling block to maintain temperature at 28 °C.  
 
2.3 Simultaneous visual stimulation and imaging of neurovascular function 
An external red light emitting diode (LED) was attached to the top of microscope chamber and 
connected to a circuit board with 220 Ω resistors in series connection to the Arduino® board 
(5V). Arduino board was controlled through custom MATLAB® 2017b scripts such that the 
LED turned ON and OFF automatically alongside imaging (set up shown in Figure 2-1A). Total 
duration of each trial was 72 seconds, with 32 seconds of pre-stimulus imaging (12 seconds of 
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laser adaptation followed by 20 seconds of actual baseline imaging) followed by 8 seconds of 
light stimulation, and eventually 32 seconds of post-stimulus or recovery imaging.  
Data was acquired at 33 frames per second (fps) with separate tracks for the red (561 nm) and 
green channel (488 nm). Each embryo underwent two trials for neurovascular function with an 
intermediate dark adaptation for 3-4 minutes. For acquiring images for vascular segmentation 
of teO, an average depth of 90-95 um was imaged for all embryos with x, y dimensions as 800 
x 600 pixels (scale: 1 pixel = 0.6 µm) (Figure 2-1B). I imaged single z plane (2D+t) of the same 
x, y dimensions as for the z stack from the superficial teO layers having visibly dense axonal 





Figure 2-1: Imaging neurovascular function in 8dpf zebrafish: A: Set up with red LED for 
simultaneous imaging and visual stimulation in LSFM. A red LED is wired to the circuit board and 
controlled through MATLAB codes via an Arduino controller board. B: 3D rendered volume of 8dpf 
old zebrafish brain showing the neuronal GCaMP3 reported labelling the neurons, mcherry labelling 
the red blood cells (RBCs) and the vascular endothelial cells. C: Single ‘z’ slice through the 3D volume 





2.4 Computational tool development for neurovascular data analysis 
2.4.1 Quantification of neuronal calcium fluorescence 
Neuronal calcium was quantified in the teO using Zen Black ® software to measure GCaMP3 
intensities for tectum and background. Relative change in fluorescence was calculated using 
the following equation:  
( ) ( )o o
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                                                                                                                         (1) 
where, F is GCaMP3 intensity in the teO, B is intensity of background area, Fo and Bo are 
baseline fluorescence (average of 10 seconds before stimulus onset) for the teO (Fo) and 











                                                                                                                                                 (2) 
where X F for teO and XB for background area, and tstim represents the time at which the 
LED is turned ON.  
I further developed an automatic analysis pipeline for characterizing the neuronal responses in 
terms of quantified measures such as: 
1. Peak frequency,  
2. Peak amplitude, and 








  was first normalized between 0 and 1 for all trials per fish, and then for all fish 
using the following: 
min( )








                                                                                                    (3) 
normF  was further de-noised using a one dimensional (1-D) wavelet based heuristic method 
(359) of smoothing (predefined function in MATLAB®2017b) where the signal (here normF ) 
was considered to be represented by: 
( ) ( ) ( )denoisednorm normF t F t e t                                                                                                      (4) 
where, time t is equally spaced, and e(t) is a Gaussian white noise with noise level 1  . The 
objective of the de-noising algorithm was to suppress the noise part of the signal ( normF ), and 
retrieve the de-noised part ( denoised
normF ). De-noising comprised of three parts: decomposition, 
detailed coefficient thresholding, and reconstruction (359), details of which are beyond the 
scope of the current section.  
Peaks are detected from the smoothened signal using a slope prominence threshold of 0.3, and 
a binary signal was created for calculating the peak frequency. The signal before calculation of 
the peaks is segregated into three time epochs: Baseline, Response and Recovery, to calculate 
the relative change in the number of peaks in response to stimulus.  
Peak amplitude was calculated using an inbuilt function in MATLAB which calculates the 




Time to peak with respect to the stimulus was calculated as a measure to compare the response 
time of the teO. It was defined as the time during the stimulus window at which the stimulus 
response peak was observed.  Peaks were observed at various times during the visual stimulus, 
but was most reliably seen in association with onset (9% of all animals), offset (78% of all 
animals) and both onset and offset (13% of all the animals) of the visual stimulus. Thus, I 
calculated the time to peak as time at which peak is observed (black arrowhead in Figure 2-2) 







Figure 2-2: Example trace showing the detection of time to peak (black arrowhead) with respect 





2.4.2 Quantification of Red blood cell speed  
I developed various analysis pipelines to analyse blood flow in different blood vessels of 
zebrafish based on pre-existing velocimetry/object tracking algorithms (360). Depending on 
the density of the red blood cells (RBC) (which depends on the size of the vessel), I used either 
centroid based object tracking algorithm (similar to digital motion analysis) (361), or pixel 
correlation based velocimetry algorithm (similar to axial line scanning) (362, 363).  
2.4.2.1 Centroid based particle tracing for velocimetry 
To analyse RBC speed, I developed MATLAB scripts based on the algorithm for velocity or 
displacement quantification within single vessels (local blood flow velocity) (361), which 
could be further extrapolated to automatically calculate blood flow velocity of larger brain 
regions (or the whole brain). Prior to the red blood cell (RBC) segmentation, vessels were 
chosen in the tectal and non tectal region of the zebrafish brain. A total of four vessels were 
chosen semi-manually from the tectum, and a further four from forebrain and hind brain 
combined. Once selected, the analysis ran automatically to segment the RBCs and eventually 
calculate the velocity profiles for each of the vessels. I designed the method by adapting the 
parameters of various pre-existing functions for image processing in MATLAB® 2017b (364) 
which had the following steps: 
 
1. Segmentation of RBCs across time using the following pipeline: 
1a.) Channel Isolation   
Red blood cells were labelled by gata1:DsRed, thus the red channel was first isolated 
from the RGB unit8 image format (default read image format in MATLAB) (Figure 
2-3 A). 
 
1b.) Median filtering 
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Non-linear median filter (365) was designed based on assigning the median value of a 
neighbourhood (W(i,j)) of a (x,y)th pixel and assigning it to the pixel (x,y) using: 
( , ) { ( , ), , }g x y med f x i y j i j W                                                                            (5) 
where, W(i,j) is the single channel isolated red image with x and y number of pixels, 
and g(i,j) is the output image post median filtering (Figure 2-3 B). 
 
1c.) Local Contrast Enhancement using ‘CLAHE’ method 
Image histogram, h(x,y) was then calculated for each of the kth luminance values using:  




                                                                                                                (6) 
where, nk is the number of pixels for k
th luminance and N is the total number of pixels. 
The histogram was then clipped at contrast limit, cl, and redistributed to generate a flat 
histogram, G(x,y).  Histogram equalization (364) was then performed within 
permissible luminance values (Lmn, Lmx) which is (0,1). 




G x y h x y


                                                                                                                     (7) 
 ( , ) ( ) ( , )out mn mn mx kL x y L L L G x y                                                                                            (8) 
where cl is the contrast limit luminance value (defining the lower limit of the clipped 
histogram), K is the upper limit of the clipped histogram and Lout(x,y) is the output 
contrasted image (Figure 2-3 C). 
 
1d.) Background subtraction 
Using a threshold, te, background image, Bg, was calculated which was then subtracted 
from contrasted image (Lout(x,y)) to get subtracted image (Isub(x,y)) 
( , ) ( , ), ( )out eBg x y L x y x y t                                                                                                     (9) 
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( , ) ( , ) ( , )sub outI x y L x y Bg x y                                                                                                   (10) 
 
where, Isub(x,y) is the background subtracted image (Figure 2-3 D). 
 
1e.) Thresholded image binarization 
Using fixed threshold, T, images were assigned 0’s and 1’s for all pixels (x,y) in image 
Isub(x,y). 










                                                                                                       (12) 
where, Ibin(x,y) is the binarized image (Figure 2-3 E). 
 
1f.) Centroid detection 
To detect position of segmented RBC, centroid (Cent) was computed by mean of pixel 
positions (366). 
1 1
( , ), ( , )bin bin
x yx y





                                                                                  (13) 
( ) ( 1)D Cent t Cent t                                                                                              (14) 
where, D is the displacement vector of the RBC centroids and (nx, ny) is the coordinate 
vector of the total number of RBC centroids detected per time frame (Figure 2-3 F-G). 
 
2. Single pixel centroids were tracked for each of the 2100 time frames of the experiment, 
with simultaneous calculation of the displacement (D) in x and y directions. The relative 
RBC speed was calculated as Euclidean norm of the displacements in x and y directions 
as follows: 




where, fps is the image acquisition rate (in frames/s), scale is the pixel to µm 





Figure 2-3: RBC tracking pipeline for velocimetry:  A: Original cropped image with focus on RBC 
passing through tectal vessel. B: Red channel image of the same tectal vessel as A. C: Median filtering 
of image in B using the de-noising algorithm. D: Contrast enhancement of image C using CLAHE. E: 
Background subtraction of image D using threshold based background selected as described. F: 
Threshold based binarization of image E. G: Red star indicates detected centroid of segmented RBC 
using the corresponding described equations. 
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The RBC speed profiles observed had a discontinuous nature since the velocity can only be 
measured when the RBCs are detected and segmented. If an RBC was not labelled with 
gata1:DsRed (which is possible, given the variability of the transgenic) it was not detected. 
Hence, the speed profile comprises of the epochs in which RBC/s were detected, segmented 
and had their speed quantified. The time epochs in which RBCs were not detected have a zero-
valued speed. In order to avoid a bias due to the zero-valued speed time epochs, I designed a 
custom interpolation method to get a non-zero continuous speed curve. The rate of interpolation 
was governed by the length of zero-valued speed epochs. Thus, the slope of increase/decrease 
of speed during those zero-valued velocity epochs depends on the difference between the 
absolute speed values surrounding the zero-speed epochs and the length of the zero-velocity 
epochs.  
Obtaining continuous RBC speed curves in this manner, I segregated speed (in µm/s) into three 
timeframes (baseline, response and recovery).  The mean values for each timeframe were 
calculated as a metric for comparison of response to baseline and recovery.  
The RBC speed for each vessel, each trial, and each fish was further characterized using metrics 
such as absolute change in speed during response compared to baseline, and time to peak 
response with respect to stimulus onset/offset wherever applicable.  
Absolute change in the velocity during response compared to the baseline time period was used 







                                                                                         (16) 
 Time to peak for RBC speed was calculated with respect to the stimulus onset, as for the 
calculation of time to peak for the neuronal calcium peak. 
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2.4.2.2 Correlation based RBC speed quantification 
While the digital motion based centroid detection method (as described in section 2.4.2.1 was 
suitable for assessing RBC speed in the cerebral vessels where vessel thickness is equivalent 
to the diameter of RBCs, a correlation based RBC speed quantification is more appropriate for 
assessing RBC speed in vessels with high RBC density. Therefore, for analysis of RBC speed 
in larger blood vessels such as the dorsal aorta, I developed a correlation based velocimetry 
method similar to that used in conventional axial line scanning method. Using self-written 
scripts in MATLAB 2017b ®, RBCs were segmented using the method described earlier 
(Figure 2-3A-F). Thresholded 2D images for each time frame were converted into 1D signal 
by summation in ‘y’ direction (all column pixels).  The 1D signal obtained was then low pass 
filtered to remove spurious and highly correlated pixels (low correlation implies the 
displacement of 1D wave signal). Cross correlation across time was calculated on filtered 
images for each time frame using an inbuilt MATLAB 2017b ® xcorr() function. Thus, the 
obtained correlation (in pixels/frames) could then be converted to mm/sec using the following 
equation: 
3( / ) 10
( / )
( / )




                                                            (17) 
 
2.4.3 Quantification of vascular anatomy 
3D stacks acquired were converted to 2D maximum intensity projections, followed by an 
automated pipeline (MATLAB) similar to RBC segmentation involving red channel isolation, 
median filtering and contrast enhancement. The remaining steps were customized for 
vasculature and comprised of the following. 
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2.4.3.1 Otsu’s method for thresholded vascular segmentation 
Contrasted images were converted to binary images using Otsu’s method of thresholding with 
parameters such as cluster size and inter-cluster threshold adjusted for the zebrafish vasculature 
datasets (Figure 2-4). Binary vasculature was then subjected to morphological thinning as 
described in the next sections. 
 
2.4.3.2 Two dimensional centreline extraction and vascular feature characterization 
Morphological thinning was applied to obtain the centerlines from the vasculature, followed 
by branch points, vessel lengths, density and diameter quantification.  
Branchpoint number, Bp(x,p), was calculated from the centreline map by automatic iterative 
search for overlapping 6 x 6 pixel regions for Y shaped 3-pixel connected structures [(i,j), (i-
1,j), (i,j-1)]   (Figure 2-5A) as described by the following: 
1, , 1 ,( , ) 1;{ , , } 1i j i j i jBp x p C C C                                                                                                     (18) 
where, p is the iteration number for 6 x 6 pixel regions in the centreline map, C. 
Vascular length (VL) was calculated as a simple summation of total white (=1) pixels of the C 





VL C                                                                                                                                    (19) 
For radius measurements, edge information was obtained from the binary segmented 
vasculature (Figure 2-5C). Radius, R, is then calculated as twice the Euclidean distance 
between the centerlines, C, and vasculature edges, E, for all the vessels using the following: 




Figure 2-4: Vascular segmentation pipeline. A: Red channel micrograph of Tg(kdrl:HRAS-mcherry) 
with the white box (marking the left optic tectum) analysed for vascular features. B: Processing steps 
in the vascular segmentation pipeline. C: Segmented binary vasculature (in magenta) overlapped with 






Figure 2-5:  Vasculature feature extraction from centreline matrix.  A: Detected branch points (in 
magenta) with their corresponding numbers marked by the algorithm in a region in the vasculature 
overlapped onto the segmented binary vasculature (in white). B: Centerlines for the same region as A 
used for quantifying the vascular length. C: Edges of the vasculature in the same region as A overlapped 
onto the centerlines to illustrate the calculated radius.  
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2.4.4 Quantification of vasculature specific klf2a and claudin5a expression 
3D image stacks acquired were first converted to 2D maximum intensity projections. I then 
segmented out the tectal vasculature from the red channel (kdrl:HRAS-mcherry), followed by 
calculation of the tectal vascular length using the method described in section 2.4.3. This 
segmented vasculature was then used as a binary mask for the green channel, followed by 
normalizing the mean intensity of the green channel (klf2a:GFP or claudin5a:GFP) to the 
tectal vascular length. This was done to remove any biases in quantification of reporters due to 
changes in the vasculature (if any). 
  
2.4.5 Quantification of tectal iGluSnFr intensity (glial cell marker) 
3D image stacks acquired were first converted to 2D maximum intensity projections. I then 
segmented out the teO followed by calculation of average intensity of the region in the green 
channel, representing expression of intensity based glutamate sensing fluorescent reporter 
(iGluSnFr). Tectal segmentation was done using MATLAB® 2017b image free hand tool, 
considering midbrain-forebrain and midbrain-hindbrain boundaries as the markers for 
segmentation.  
 
2.4.6 Intensity based quantification of heart rate 
As described earlier, each stimulation trial comprised of 32 seconds of baseline, followed by 8 
seconds of light stimulation, and then 32 seconds of post stimulus imaging. I performed the 
same paradigm imaging the heart instead of the teO to observe any changes due to systemic 
effects of the light stimulation protocol. With single plane imaging, structural changes in a 
beating heart can be assessed by quantification of the average changes in the red fluorescence 
(from the labelled RBCs). This caused changes in the intensity of ventricle selected on the 
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surface of the heart plane of imaging. Thus using the average changes in intensity of the red 
channel on the specific area, a waveform of heart rate as a measure of heart beat was obtained. 
For my measurements, I selected the in plane ventricular region as the region for quantification 
of average intensity. I measured the frequency of peaks to get a peaks/min equivalent to 
beats/min as an estimate of heart rate. Subsequently, I segregated the complete heart rate signal 
into the three time periods (baseline, response and recovery) as described for the neuronal and 
RBC speed quantification.  
 
2.5  Drug treatment 
All the drugs were acquired from SIGMA ® and administered through bath application. Bath 
application was of overnight duration (14-16 h), unless otherwise specified. 
 
2.5.1 Nitric oxide synthase inhibition 
For NOS inhibition experiments 0.5mM N(ω)-nitro-L-arginine methyl ester (L-NAME) was 
prepared in E3 media and administered at 7dpf, with larvae imaged using LSFM at 8dpf. 
 
2.5.2 Cyclooxygenase inhibition 
10µM of Indomethacin was used for non-specific COX (1 and 2) inhibition. Indomethacin 
was made up using 0.1% dimethyl sulfoxide (DMSO), and applied to the bath from 7dpf, 




2.5.3 Glucose/Mannitol administration for hyperglycemia experiments 
Glucose and mannitol (Sigma®) were prepared at 20mM concentration in E3 media. Larvae 
were exposed to glucose or mannitol solution from 4 dpf-9 dpf (chronic administration), with 
solution replaced every day after 5.2 dpf until 9 dpf.   
For testing the effect of acute glucose administration, larvae were fed with Gemma Micro ® 
from 4-8 dpf, followed by addition of glucose from 8-9 dpf. The same procedure was repeated 
for acute mannitol treatment.  
 
2.5.4 Sodium nitroprusside treatment  
For hyperglycemia experiments, 100mM stock solution of sodium nitroprusside (SNP) 
(Sigma®) was diluted to 0.1mM in either 20mM glucose and mannitol solutions comprising 8 
dpf larvae, followed by imaging on LSFM at 9 dpf (24 h treatment).   
 
2.5.5 TRPV4 antagonist treatment 
For blocking TRPV4 activity, 100mM stock solution of TRPV4 antagonist III (Sigma®) was 
diluted to 0.2mM in E3 and applied to the bath from 7 dpf, followed by imaging using LSFM 
at 8dpf. 
 
2.5.6 Assessment of NO reactivity in the brain vessels 
For quantification of NO levels in the vascular and/or brain tissue, 9 dpf zebrafish larvae with 
mannitol/glucose with/without SNP were treated with 2.5 µM Diaminofluorescein-FM (DAF-
FM). For preparing stock solutions, lysophilized DAF-FM was solubilized in DMSO to a stock 
concentration of 0.1mM and stored at -20°C. On the day of experiments, DAF-FM stocks were 
diluted to a concentration of 2.5µM in either glucose or mannitol solution. Zebrafish larvae 
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were then incubated in the solutions at 28°C in the incubator, in the dark, for 3 hours. Larvae 
were then visualized under a fluorescent microscope (Zeiss Axiocam 503) to check staining in 
the green channel, and staining was continued for another half hour with constant checking of 
stain intensity. Larvae were washed with glucose/mannitol solution to wash off excess DAF-
FM, and then imaged on the LSFM.  
 
2.6 Genotyping protocol for gch1 mutants 
NVC measurements were performed post 6 dpf for all experiments, including when evaluating 
NVC in gch1 mutants (generated by Dr. Marcus Keating and Prof. Oliver Bandmann). 
Heterozygous gch1 mutants with 94 base pair (bp) deletion (Figure 2-6) were crossed into the 
triple transgenic neurovascular line Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed). 
Embryos from this cross were selected for green neuronal calcium, red RBCs, and red ECs at 








For genomic DNA (gDNA) extraction, a small amount of tail tissue was dissected from 
anesthetized 3 dpf embryos using a sterilized scalpel blade, followed by suspension in 15mM 
NaOH in a 96 well PCR plate. This was then incubated at 95°C for 10 minutes for tissue lysis, 
followed by inactivation with 1/10 volume of 1M Tris-HCl (pH 8.0) neutralisation buffer. 
 
Extracted gDNA was used for per tube for a 10 µl PCR reaction with the composition described 
in Table 2-2. 
PCR mix content Volume (in µl) 
Biomix Red (Invitrogen) 5 
Forward primer 1 
Reverse primer 1 
Diethylypyrocarbonate (DEPC) water 2 
Extracted gDNA 1 
 10 (total) 
Table 2-2: Table describing the composition of the PCR mix with the corresponding volumes. 
 
The specific primers (IDT) for gch1 were prepared using Diethyly Pyrocarbonate (DEPC) 
water and diluted at 1:10 with DEPC water for working concentrations. The primer sequences 
are as follows: 
Forward Primer 5’- AAACTGACGGAGCGATCAAC 
Reverse Primer 5’- TCTCCTGGTATCCCTTGGTG 
 PCR reaction was mixed with gentle pipetting up and down, followed by amplification on a 
PCR machine (Multigene Optimax) using the PCR60 (with annealing temperature 60°C) 
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Wild types, heterozygous and homozygous mutants were selected based on singe/double band 
obtained on gel electrophoresis of the PCR products run against 100 base pair (bp) ladder 








Figure 2-7: PCR amplicons for wildtype (gch1(+/+)) of size of 300 bp, heterozygous (gch1(+/-)) 
with band sizes 300 bp and 206 bp, respectively and homozygous (gch1(-/-)) siblings with band 






2.7 Behavioural analysis 
2.7.1 General locomotion analysis with Viewpoint-Zebrabox system 
All locomotion was analysed using the Viewpoint-Zebrabox system. For general locomotion 
analysis one larva was placed per well in a 96 well plate, each well filled with a volume of 800 
µl E3. The plate was placed inside the Zebrabox, with light settings at 1% intensity, and left 
for 10mins prior to actual experimental recording to allow the larvae to acclimatize While the 
larvae were acclimatizing the tracking protocol was built using the viewpoint tracking software, 
wherein a region of interest (ROI) was manually drawn on the wells positioned top left, top 
right and bottom right for the software to build automatically for all ROIs corresponding to 
each well in the 96 well plate. Total length for the complete plate was selected as 107 mm, 
followed by setting zebrafish detection intensity threshold to 115 intensity units which was 
then calibrated for the complete plate. Speed thresholds were set for large movement at 
64mm/s, small movement at 33-64 mm/s, and anything less than 33mm/s to be classed as 
inactivity to analyse various types of locomotion. Sampling time was set to one minute and the 
movie was acquired for 30 minutes once the 10 min acclimatization was complete. Data was 
generated in the form of excel files, and was then analysed for parameters such as distance 




2.7.2 Light/Dark preference test with Viewpoint-Zebrabox system 
Analysis of Light/Dark preference of the larval zebrafish was designed on a similar principle 
to that of the adult light/dark preference test (299). A 12-welled plate was modified by adhering 
three cellophane films (blue, green and yellow) to half of each well to create a ‘dark’ side but 
keep enough visibility for the camera to track the larvae movement through infrared (IR) 
camera.  Alternate sides of the wells were darkened (also using cellophane) in order to avoid 
bias due to left-right preference in zebrafish (if any) (schematic shown in Figure 2-8).  
Each well of the 12 welled plate was labelled as an arena for an individual animal. Parameters 
for the imaging were as described in 2.8.1 above for locomotion analysis. Larvae were imaged 
for a one-hour duration, inclusive of the acclimatization (recording was started immediately 
post adding larvae to individual well).  
Post imaging, basic features such as time spent in light vs dark, distance travelled in dark vs 
light, with inter-group comparisons, were computed from the excel spreadsheets imported from 
the viewpoint tracking system. Quantitative data for each of the animal was obtained by 





Figure 2-8: Schematic representation of the half darkened wells of a 12 well plate used for 
light/dark preference test for larval zebrafish. Dark side of each of the wells represent cellophane 





Immunohistochemistry (IHC) was used to observe and quantify changes in glial specific 
markers such as glutamine synthetase (GS), GFAP, and TRPV4. The protocol was adapted 
from (368). The various steps in the protocol are described as follows including reagent 
preparation (Table 2-3). All the steps were carried out for 30-50 larvae per 1.5 ml Eppendorf 
tube with 1 ml of reagents (or lesser volume enough to cover all the larvae in the tube). 
 
2.8.1 Reagent preparation 




1x PBS (1 PBS tablet 
in 100 ml MilliQ) with 
0.1% Tween 
Working PBS-
Tween is made 
in 50 ml aliquots 
with dilution of 





Tris- HCl 150mM Tris Buffer 
with HCl 
 5M HCl/ NaOH 
pellets were used 





10% sheep serum, 
0.8% Triton-X100, 1% 
Bovine Serum 





1% sheep serum, 0.8% 
Triton-X100, 1% BSA 
in PBST 






PBS with Triton and 
Sheep Serum (PBS-
TS) 
10% sheep serum, 1% 
Triton-X100 in PBS 
 4°C 
Table 2-3: Table describing the various reagents for IHC protocol with their corresponding composition 




2.8.2 Larval fixation 
Larvae for each different treatment (mannitol or glucose, with or without co-treatment with 
SNP) were fixed in 4% Paraformaldehyde (PFA) for overnight at 4°C followed by a 5min wash 
with 1x PBS before re-suspending in 100% Methanol (MeOH) for long term storage at -20°C.  
 
2.8.3 Sample rehydration and equilibration 
Larvae were rehydrated from MeOH with three 10min washes with PBST, with gentle agitation 
on a rocker (with tubes aligned along their side). 
 
2.8.4 Heating procedure 
Larvae were then suspended in 150 mM Tris-HCl (pH 9) for 5 minutes, followed by heating at 
70°C for 15 minutes. Larvae then underwent two 10min washes with PBST, followed by two 
5min washes with distilled water (dH2O).  
 
2.8.5 Permeabilization 
Larvae were permeabilised using ice cold acetone at -20°C for 20 minutes, followed by two 
5min washes with dH2O, then equilibrated twice with 5min washes in PBST.  
 
2.8.6 Blocking and 1° Ab incubation  
For the initial blocking stage, larvae were incubated in blocking buffer (B-buffer) for 3 hours 
at 4°C.  B-buffer was removed and the larvae were then incubated in I-buffer containing the 1° 
Abs listed in Table 2-4, for 3 days at 4°C with gentle agitation on a rocker.  
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Residual primary antibody residue was removed by three 1 hour washes in PBST (at room 
temperature (RT)). Larvae then underwent two 10min washes with PBS-Triton, followed by 
two equilibration washes in PBS-TS, for 1 hour each.  
Primary Antibody Host Organism Dilution 
Glutamine Synthetase (GS) Mouse 1:250 
GFAP Mouse 1:100 
TRPV4 Rabbit 1:300 
DAPI - 1:1000 
Table 2-4: Table listing the primary antibodies used, with their corresponding host organisms and 
dilutions. 
 
2.8.7  Equilibration and 2° Ab incubation 
Larvae were incubated in I-buffer containing secondary antibodies listed in Table 2-5, at 1:500 
dilutions for 2.5 days, in the dark on a rocker at 4°C.  
Prior to imaging on the Lightsheet microscope, larvae were washed three times in PBS-TS (at 
RT), followed by two 1 hour washes with PBST, each at RT. Larvae were mounted in 1% LMP 
(Sigma) and imaged for the glial patterning in the brain for different markers.  
Secondary Antibody Wavelength (nm) Dilution 
Anti- mouse 647 (Far red) 1:500 
Anti-rabbit 488 (Green) 1:500 
Anti-rabbit 561 (Red) 1:500 
Table 2-5: Table listing the secondary antibodies used, with the corresponding wavelengths of the 
conjugated fluorophores and dilutions, respectively. 
 
2.9 Experimental design and statistical analysis 
All experiments were designed using the NC3Rs experimental design analysis (EDA) tool. 
GraphPad Prism (La Jolla, CA®) was used for all statistical comparisons. Shapiro-Wilk test 
for normality was performed prior to statistical analysis. Neuronal calcium peaks and RBC 
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speed in different time periods were compared either using parametric one-way repeated 
measure analysis of variance (RM-ANOVA) for normally distributed data or Friedman’s test, 
otherwise. All the intergroup comparisons of neuronal activations and RBC speed between 
different time periods (baseline, response and recovery) for various treatments 
(drugs/mannitol/glucose) were performed using two-way ANOVA. Post-hoc multiple 
comparison tests (Sidak’s test) were used for all the ANOVA tests. Comparison of tectal and 
non tectal RBC speed changes in response to visual stimulation were done using paired t-tests 
or one-way ANOVA in case of more than two groups. P values <0.05 were considered to be 
statistically significant. All the data are mean ± standard error of mean (s.e.m.), unless 
otherwise specified. Imaging was performed unblinded to the treatment allocation. Most of the 
data analysis was automated hence not subjected to operator bias. Wherever the data was semi-
automated, blinded analysis was performed.  
 
2.10 Development of computational model of neurovascular coupling 
In this section, I have described the equations used to simulate NVC in a minimal model of 
NVU. Neuron, astrocyte and vessel model equations are adapted from pre-existing models with 
modifications to simulate eight second stimulation, as used for the experimental zebrafish 
model. Each of the component in the NVU modelled in the present thesis is described with its 





Figure 2-9: Schematic representation of the neurovascular unit showing the connections between 
each of the compartments (Neuron: N, astrocyte: A and blood vessel: V). Each of the compartments 
is an input/output system with output of each of the compartment acting as the input to the next. Input 
to the neuron is the external current, I
ext
 and the output is glutamate released. Input to the astrocyte is 
the glutamate released from the neuron and output is vasodilator EET released that acts as the input to 
the vessel compartment. Blood vessel dilation (diameter changes) is the output of the vessel 
compartment and a feedback input to the astrocyte compartment (activating the TRPV4 current). 









2.10.1  Neuron Model 
 
Neuronal spike dynamics are described using standard quadratic integrate and fire (QIF) (369) 
using the following equations: 
( )( ) ( )th rest ext
dV
a V V V V I threshold a
dt
                                                                            (21) 
where V represents the neuronal membrane potential, Vth being the spiking threshold, Vrest as the 
resting membrane potential, a representing the QIF parameter, Iext representing the external 
stimulus current and threshold is the negative control reducing the threshold of neuronal firing 
as a function of adenosine released by the astrocyte compartment.  
Neuronal firing leads to release in glutamate (Glut) in the synaptic cleft and is modelled as a 





                                                                                                       (22) 
where H(V-θ) represents the step function (H: heaviside) of V with a threshold (θ) and α is the 
glutamate decay parameter.  




























VK -100 mV 
Surface area (sa) 1586 mµm2 
Volume 2160 mµm3 
Faraday’s constant (F) 96500 C/mol 
dt (time constant for simulations) 0.01 
Table 2-6: Table listing all the neuronal model parameters with their corresponding values used 
for simulations 
 
2.10.2 Astrocyte Model 
 
The astrocyte model is adapted from (334) modelling the binding of glutamate to the mgluR 









                                                                                                                       (23) 
 where δ is the ratio of activities of bound to unbound receptors and ρ is the ratio of bound to 






                                                                                                                      (24) 
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The binding of synaptic glutamate to the astrocyte mGluR leads to the production of  inositol 






r G k IP
dt
                                                                                                              (25) 
where, rh is the [IP3] production rate and kdeg is the destruction rate.  
[IP3] production leads to the activation of IP3 receptors on the endoplasmic reticulum leading 
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                                                            (26) 
where, Jmax is the maximum rate, Kl is the dissociation constant for calcium binding to n 
activation site on the IP3 receptors and CaER is the calcium concentration in the endoplasmic 
reticulum (ER). The gating variable h is modelled as in  (334) and is given by: 
2([ ] )on inh i inh
dh
k K Ca K h
dt
                                                                                                  (27)                                                                                         
where kon and Kinh are the Ca
2+ binding and dissociation constants, respectively at the inhibitory 
IP3 receptor binding site. 
Astrocyte intracellular calcium, [Ca2+] (eq.28) is modelled to be minimally dependent on IP3 





( )i IP pump leak TRPV
d Ca




                                                                                      (28) 
where, [Ca2+]is the cytosolic calcium concentration in astrocyte, Jpump represents the Ca
2+ flux 
from the cytosol to endoplasmic reticulum (eq.29), Jleak is the Ca
2+ leak flux from the 
































                                                                                                              (30) 
where Vmax is the maximum pump rate, Kp is the pump constant and PL is determined by steady 
state flux balance.  
Calcium influx from the extracellular flux, JTRPV4 depends on the arteriolar tone (considered to 









                                                                                                                       (31) 
where Castr is the astrocyte capacitance, γ is the scaling factor described by (334), and ITRPV4 is 
the current through the channel given by: 
4 4 4( )TRPV TRPV k TRPVI g s V v                                                                                                        (32) 
where gTRPV4 is the maximal channel conductance, vk is the channel reversal potential, Vk is the 








                                                                                                                    (33) 
where CaP is the perivascular calcium concentration (µM) and is assumed to change slowly 
and hence static. τTRPV4 is the time constant for TRPV4 channel. s∞ is the strain and Ca 
dependent steady state channel open probability and is given by the Boltzmann equation as 
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              
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where ε is the strain parameter and depends on changes in cerebral vascular tone (modelled as 




 are the channel constants adapted from 
Withoft et al. Vk is the astrocyte membrane potential and HCa is the inhibitory term given by 
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where VEET is the EET production rate, Camin is the minimum calcium required for EET 
production and kEET is the EET decay rate, all adapted (334). EET being a vasodilator impacts 
the blood flow through changes in vascular NO described in eq.38. Various constants used in 











Kdeg 1.25 /s 
Β 0.0244 
KL 0.03 µM 
Kact 0.17 µM 
kon 2 µM/s 
Kinh 0.1 µM 
CaER 400 µM 
Vmax 20 µM/s 
KP 0.24 µM 
PL 5.2 µM/s 
v
TRPV4
 6 mV 
g
TRPV4
 200 pS 
Cast 40 pF 
Γ 1970 mV/ µM 




 0.2 µM 
γ
Cae
 0.2 µM 
v
1,TRPV4
 120 mV 
v
2,TRPV4
 12 mV 
τ
Ca
 0.9 /s 
V
EET
 72 /s 
Ca
min
 0.1 µM 
K
EET
 7.1 /s 
G
Leak
 78.54 pS 





 0.5 /s 
Ca
P0
 2000 µM 
α  1 
V
4,BK
 14.5 mV 
V
5,BK
 8 mV 
V
6,BK
 -15 mV 
Ca
3,BK
 400 nM 
Ca
4,BK
 150 nM 
ψ
BK
 2.665 /s 
EETshift 2 mV 
g
BK
 225.6 pS 
V
BK
 -95 mV 
Table 2-7: Table listing all the astrocyte model parameters used for simulations 
 
2.10.3 Blood vessel model 
 
To keep the model simple and minimal, I have developed a lumped two-variable (NO and 
diameter, D) model of the blood vessel wherein vessel diameter changes are dependent on the 
NO levels in the blood vessel. EET released from the astrocytes increase vascular NO (given 
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                                                               (38) 
where, α represents the NO diffusion constant in the vessel for a given area, G
max
 is set 
maximum glucose level (=20mM) to represent the upper hyperglycemic threshold and G is the 
model glucose parameter used to switch from normoglycemic (G = 5mM) to hyperglycemic 




( ) ( )( )f NO NO NO p NO q                                                                                                 (39) 
f(EET) is a heaviside function of EET released by astrocyte and is given by eq. 40.                                                                                                                                                                                                                                                                         
( ) ( )f EET H EET e                                                                                                              (40) 
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 where, ω and ρ are model parameters fixed for the simulations. Various other constants used 













Blood vessel parameters  




















3 Developing a model of neurovascular coupling in zebrafish  
 
3.1  Aims  
This chapter describes the development and characterization of a novel non-invasive zebrafish 
model of NVC. My aim was to determine whether visual stimulus led to a specific increase in 
neuronal calcium in the teO and a corresponding increase in the RBC speed in the optic tectal 
blood vessels.  I quantified and compared this response at different stages of zebrafish 
development. I also explore the mechanisms of NVC in zebrafish such as direct (NO 
dependent) or indirect (glial/COX dependent) pathways known to contribute to NVC in 
mammals. 
 
3.2 Visual stimulus induces specific increases in fluorescence in the optic tectum 
of 8 dpf Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed) larvae 
To investigate the presence of NVC, I first sought to induce and quantify visual stimulus-
evoked neuronal activation in Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed). Individual 
animals were embedded in agarose within the lightsheet microscope chamber as described in 
section 2.2. The plane of imaging focused on the dendritic fibre-like structure in the superficial 
layers of the teO. After 32 seconds of baseline imaging, the animal was exposed to a red light 
square pulse of 8 seconds duration followed by 32 seconds of recovery imaging. I quantified 
tectal fluorescence as ΔF/Fo as described in section 2.4.1. Figure 3-1A shows representative 
images of the left teO during these experiments. Increases in the fluorescent intensity of 
neuronal GCaMP3 (shown in green) were observed in response to visual stimulus before 
returning to baseline 14 s after stimulus. This increase in fluorescence represents an increase 
in neuronal calcium levels indicating increased neuronal activity. On quantification of the 
99 
 
neuronal responses (expressed as ΔF/Fo) I observed peaks at various times during the visual 
stimulus but peaks were most reliably seen in association with onset (9% of animals), offset 
(78% of animals) and both onset and offset (13% of animals) of the visual stimulus. 
Representative examples are shown in Figure 3-1B-C. 
Since most neuronal calcium peaks were observed in response to stimulus offset (78%), 
averaging the responses of five larvae reveals a robust peak in neuronal calcium at stimulus 
offset (Figure 3-2A). To quantify the response, I divided the time series shown in Figure 3-
2A into three time periods (as described in section 2.6.1), baseline, response and recovery. I 
observed significant increases in the average frequency of neuronal calcium peaks during the 





Figure 3-1: Visual stimulus induces optic tectal calcium responses to 8 s visual stimulation in 8 
dpf zebrafish. A: The left optic tectum of an 8 dpf Tg(nbt:GCaMP3; kdrl:mCherry;gata1:DsRED) 
embryo before (-10s), during (2s and 8.3s) and after (14s) visual stimulus by red light. Arrow indicates 
area of increased tectal calcium levels in response to the stimulus. B-D: Quantification of neuronal 
activation (ΔF/Fo) in the optic tectum in three individual larvae, showing neuronal calcium peaks at 
stimulus ON, stimulus OFF and both stimulus ON and OFF. Visual stimulus was administered 0-8s 




 Figure 3-2:Average neuronal calcium response in the optic tectum to visual stimulus in 8 dpf 
larvae. A: Quantification of neuronal activation (ΔF/Fo) in optic tectum over time (n=5 larvae). Visual 
stimulus was administered 0-8s (indicated on graph by red bar). Time-series was divided into baseline 
(-10-0s), response (0-20s), and recovery (20-30s) periods. B:  Quantification of frequency of peaks in 
(ΔF/Fo) as a measure of neuronal activation during baseline, response and recovery time periods (n=40 
larvae). Data in A is mean ± s.d. and B is mean ± s.e.m. **p<0.01, ****p<0.0001 (Friedman’s test) 
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3.3 Tectal neuronal calcium peak onsets demonstrate a decreasing trend with 
increasing the stimulus duration  
 
To examine the relationship between stimulus duration and neuronal calcium response, and to 
optimise my protocol to find the stimulus that induced the greatest neuronal activation, I 
quantified neuronal peak frequency in response to different durations of stimulus (4, 8 and 12 
seconds). The response was not significantly different between these stimulus durations 
(Figure 3-3A-D). I quantified the speed of peak onset (quantified as time to half peak, t1/2) but 
found only a non-significant trend to a faster onset with increasing stimulus duration between 




Figure 3-3: Neuronal calcium peak activation in the optic tectum of 8 dpf zebrafish in response 
to different stimulus durations. A-C: Quantification of neuronal calcium peak responses to 4, 8 and 
12 s visual stimulation (n=5 larvae/group).  Visual stimulus was administered 0-8s (indicated on the 
graphs by red bar). D: Change in the neuronal calcium peak frequency during response compared to 
baseline for 4,8 and 12 seconds of light stimulus (n=14, 15 and 12 larvae for 4, 8 and 12s, respectively, 
at 8 dpf). E: Peak onset time expressed as time to half peak (t1/2) for 4,8 and 12s stimulus duration for 
same animals as in A. Data in A-C are mean ± s.d. and D-E are mean ± s.e.m (Friedman’s test used for 





3.4 Visual stimulus induces specific increases in the RBC speed in 
Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed) larvae 
 
Having observed prominent neuronal calcium peaks in response to visual stimulus, I next 
quantified RBC speed in blood vessels in the teO of 8 dpf larvae.  Using the method described 
in section 2.4.2.1, I quantified RBC speed changes in the tectal vessels in the imaging plane. 
Representative example of RBC tracking during different time periods of the experiments is 
shown in Figure 3-4A. As I observed neuronal calcium peaks at both onset and offset of the 
visual stimulus (as described in section 3.2), I then quantified the corresponding RBC changes 
in the same animals shown in Figure 3-1B-D. Figure 3-4B-D shows the RBC speed increases 
for onset and/or offset of the stimulus.  
I then quantified a mean RBC speed for a group of five larvae (same animals as in Figure 3-
2A) and observed a prominent peak in RBC speed at ~13.5 s with respect to stimulus onset 
(Figure 3-6A).  For further quantification, I segregated the time series for all the animals into 
three time periods (as described in section 2.4.1), baseline, response and recovery.  I observed 
statistically significant increases in mean RBC speed during the response time period compared 




Figure 3-4: RBC speed changes in the optic tectum of 8 dpf zebrafish in response to 8s visual 
stimulation. A: Segmented RBCs shown for two consecutive frames (Framen and Framen+1) for 
corresponding time point of the neuronal responses shown in Figure 3-1A. Individual RBCs are 
labelled in green to represent Framen and magenta to represent Framen+1. B: Quantification of RBC 
speed in the blood vessels in the optic tectum over time, showing examples where neuronal calcium 
peaks occurred at stimulus ON, stimulus OFF and both stimulus ON and OFF. Visual stimulus is 





Figure 3-5: RBC speed changes in response to visual stimulation. A: Erythrocyte (RBC) speed in 
tectal vessels in the same animals as Figure 3-1. B: Mean RBC speed in the tectal vessels during 
baseline, response and recovery time periods in the same animals as Figure 3-1. Data in A is mean ± 






3.5 Red blood cell speed is not statistically different in groups with different 
duration of light stimulation 
 
As described in section 3.3, onset times to neuronal calcium peaks showed a decreasing trend 
with increasing stimulus duration. I then quantified the differences in the RBC speed in 
response to different duration of stimulus (4, 6 and 12 seconds). No significant differences 




Figure 3-6: RBC speed changes in response to different stimulus duration. A-C: Quantification of 
RBC speed in response to 4, 8 and 12s visual stimulation (n= 5 larvae/group). Visual stimulus is 
delivered for 0-8s shown by red bar on the graphs. D: Change in RBC speed during response time 
period compared to baseline for 4,8 and 12s stimulus duration for same animals (n=14, 15 and 12 larvae 
for 4, 8 and 12s, respectively) as in Figure 3-3. Data in A-C is mean ± s.d. and D is mean ± s.e.m (one-
way ANOVA).  
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3.6  Light stimulus associated neuronal calcium peak and blood velocity peak 
are temporally coupled 
 
On comparing the mean time to peak of neuronal activation and RBC speed, I found the RBC 
speed peak to be delayed by 6.33±3.19 s from the neuronal calcium activations (Figure 3-7), 
suggesting a delayed coupling of the vascular responses, similar to the response in mammalian 






Figure 3-7: Temporal relationships between stimulus onset, change in neuronal activations and 
RBC speed. Quantification of mean time to peak for neuronal calcium responses (ΔF/Fo) and RBC 






3.7  Neurovascular responses in response to light stimulation are spatially 
restricted to the optic tectum 
 
To determine the spatial specificity of the RBC response, I measured RBC speed in the blood 
vessels in forebrain and hindbrain (i.e. non tectal vessels) and dorsal aorta. Representative 
images are shown in Figure 3-8A. Quantification of mean RBC speed in response to visual 
stimulus showed no significant difference in the response period compared to baseline unlike 
in the tectal vessels (See section 3.4 and 3.5) Figure 3-8B. Comparing the absolute change in 
RBC speed, I found stimulus associated increases in the RBC speed in the tectal vessels to be 
significantly higher than non tectal vessels Figure 3-8C.  This suggests a local blood flow 




Figure 3-8: Spatial specificity of increase in RBC speed in response to visual stimulus in tectal 
compared to non tectal blood vessels. A: Representative micrograph of 
Tg(nbt:GCaMP3;kdrl:mcherry) showing tectal and non-tectal vessels in the brain of 8 dpf old zebrafish. 
B: Representative micrograph showing the location of dorsal aorta for quantification of RBC speed 
comparisons in C and D. C: Baseline RBC speed in tectal vessels, non-tectal (hindbrain and forebrain) 
vessels and dorsal aorta. D: RBC speed expressed as percentage from the baseline for baseline, response 
and recovery for tectal vessels, non-tectal vessels and dorsal aorta (n=17 larvae/group). Data in C-D are 





3.8  Light stimulation does not affect heart rate 
 
To examine the possibility that systemic effects were responsible for changes in RBC speed in 
the teO, I measured the heart rate in response to visual stimulus (as described in section 2.4.6). 
Since the compound transgenic (Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed)) labels 
the red blood cells I quantified the change in the red channel intensity averaged over the 
ventricular area for the three time periods (baseline, response and recovery). The change in 
intensity for a typical quantification is shown in Figure 3-9. I then calculated the number of 
peaks from the signal obtained. I found that visual stimulation had no effect on the heart rate 
when comparing peak frequency of the heart rate signal during the response time period 
compared to baseline Figure 3-9. This confirms that the changes in RBC speed in the teO are 




Figure 3-9: Effect of visual stimulation on heart rate. A: Representative micrographs showing a 
systole and a diastole (white arrowhead) corresponding to one peak on the time series graph on B. C. 
Quantification of heart rate as beats per minute (bpm) during all baseline, response and recovery time 





3.9  Neurovascular coupling in zebrafish is not evident until 6 dpf 
 
Studies have shown rodents develop NVC only after a certain period in development (134, 137, 
372). I therefore examined the neurovascular responses to light stimulation at 4, 6 and 8 dpf to 
detect whether zebrafish display a similar developmental threshold. Quantification of the 
neuronal response to visual stimulation for baseline, response and recovery found no stimulus 
evoked neuronal calcium peaks at 4 dpf but these were present at 6 dpf (Figure 3-10). 
Comparing the mean RBC speeds for the same animals, I found no significant changes in RBC 
speed either at 4 or 6 dpf (Figure 3-10). This suggests in spite of having stimulus evoked 




Figure 3-10: Neurovascular coupling in zebrafish develops after 6 dpf. A: Quantification of 
frequency of peaks in (ΔF/Fo) as a measure of neuronal activation during the baseline, response and 
recovery time periods for 4d and 6d post fertilization (n=17 larvae/group). B: Mean RBC speed during 
baseline, response and recovery time periods in the same animals as A (n=17 larvae/group).  C: Mean 
baseline RBC speed in tectal vessels in 4, 6 and 8 dpf zebrafish. D: Change in RBC speed (ΔRBC) in 
response to stimulus in 4, 6, and 8 dpf (n=17 larvae/group). *p<0.05, **p<0.01. Data in A-D are mean 




3.10  Nitric oxide synthase inhibition prevents the increase in RBC speed in tectal 
vessels in response to visual stimulation 
 
I next tested the effect of the NOS inhibitor L-NAME on NVC. I incubated 7 dpf zebrafish 
with 0.5mM L-NAME in E3 or E3 alone and imaged them at 8 dpf (16-18 h treatment). 
Following imaging, I quantified change in neuronal calcium fluorescence (quantified as ΔF/Fo) 
and corresponding RBC speed in both groups (time series shown in Figure 3-11A-B). I 
observed both E3 and L-NAME groups responded to visual stimulation by increasing neuronal 
calcium peak frequency during the response time period compared to baseline and recovery 
(Figure 3-12A). However, in the L-NAME treated larvae, RBC speed did not increase during 
the response time period compared to baseline and recovery (Figure 3-12B). L-NAME 
significantly reduced the change in the RBC speed during the response time period compared 




Figure 3-11: Nitric oxide inhibition causes neurovascular uncoupling. Quantification of neuronal 
activation (ΔF/Fo) in the optic tectum and RBC speed for 8 s visual stimulus for A: controls (E3) and 
B: L-NAME treated 8 dpf Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed) larvae (n=5 
larvae/group). Visual stimulus is delivered for 0-8s shown by red bar on the graphs. Data in A-B is 






Figure 3-12: Nitric oxide inhibition prevents neurovascular coupling in 8 dpf zebrafish. A: 
Quantification of frequency of peaks in (ΔF/Fo) as a measure of neuronal activation during the baseline, 
response and recovery time periods for E3 (n=36 larvae) and L-NAME treated groups (n=32 larvae). 
B: Mean RBC speed during baseline, response and recovery time periods in the same animals as A. C: 
Change in RBC speed (ΔRBC) in response to stimulus. Data in A-C are mean ± s.e.m. *p<0.05, 
**p<0.01, ****p<0.0001 (two-way ANOVA and unpaired t-test for A-B and C, respectively). 
120 
 
3.11  Cyclooxygenase inhibition reduced neurovascular coupling in zebrafish 
 
I next tested the presence of an indirect pathway of NVC mediated by cyclo-oxygenase as 
shown in mammalian models. Using a non-specific COX inhibitor, indomethacin (10 µM) for 
overnight incubation (16-18 h), I quantified the changes in the neuronal calcium fluorescence 
in the teO (ΔF/Fo) and RBC speed in response to 8 s visual stimulation (Figure 3-13A-B) for 
0.1% DMSO (control) and indomethacin treated groups. Both DMSO and indomethacin treated 
larvae showed significantly increased neuronal calcium peak frequency during the response 
time period compared to baseline and recovery (Figure 3-14A). However, indomethacin 




Figure 3-13: COX inhibition causes neurovascular uncoupling. Quantification of neuronal activation 
(ΔF/Fo) in the optic tectum and RBC speed for 8 s visual stimulus for A: controls (DMSO) and B: 
Indomethacin treated 8 dpf Tg(nbt:GCaMP3;kdrl:HRAS-mcherry;gata1:DsRed) larvae (n=5 
larvae/group). Visual stimulus is delivered for 0-8s shown by red bar on the graphs. Data in A-B is 






Figure 3-14: COX inhibition causes neurovascular uncoupling. A: Quantification of frequency of 
peaks in (ΔF/Fo) as a measure of neuronal activation during the baseline, response and recovery time 
periods for E3 (n=28 larvae) and Indomethacin treated groups (n=26 larvae). B: Mean RBC speed 
during baseline, response and recovery time periods in the same animals as A. C: Change in RBC speed 
(ΔRBC) in response to stimulus. Data in A and B are mean ± s.e.m. *p<0.05, **p<0.01, 





I here describe a novel larval zebrafish model of NVC. On stimulation with 8 seconds of red 
light I found increases in neuronal calcium and RBC speed in the teO.  I have then shown that 
the teO neurons can respond phasically at ON or OFF or both depending on the layer of SPV 
being imaged (294). Zebrafish tectal neuropil is densely populated with periventricular layer 
(PVL) interneurons which could explain majority of the responses being in response to turning 
off the light stimulus (373).  I demonstrated the local specificity of the neurovascular responses 
by showing increases in RBC speed were confined to the teO and not detected in blood vessels 
in the hindbrain and/or the forebrain. I found no evidence of a systemic effect of the stimulation 
as the stimulus induced no change in dorsal aorta RBC speed or heart rate. I therefore conclude 
that zebrafish do indeed display NVC analogous to the response that has previously only been 
described in mammals. I found that zebrafish demonstrate a developmental threshold for NVC 
as they do not display NVC until after 6 dpf. Furthermore, neuronal calcium responses are 
spontaneous till 6 dpf, a marker of development of neuronal circuitry similar to shown in 
neonatal mammalian reports (134, 137).  
Mammalian studies have shown NVC can be modulated by multiple redundant mechanisms. 
In mammals, local regulation of blood flow is known to occur via neuronally derived signals 
such as glutamate and NO (374). Further work also suggested mechanisms involving astrocytes 
(38), interneurons (26) and pericytes (82). However, the exact role of various cellular 
candidates is under debate, for example COX-mediated astrocyte regulation of blood flow has 
been suggested to be involved in indirect, rather than direct regulation of blood flow (26, 48). 
I have tested the presence of NO and COX based mechanisms in the zebrafish model of NVC 
by using L-NAME (non-specific NOS inhibitor) and Indomethacin (non-specific COX 
inhibitor). I found that inhibition of either the NOS or COX-mediated pathways resulted in 
inhibition of the RBC speed increase associated with visual stimulation in 8 dpf zebrafish 
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larvae. This suggests that both NO and COX based mechanisms of neurovascular coupling 
exist in zebrafish. There is an ongoing debate on specific contribution of neuronal COX (COX2 
in pyramidal neurons) and astrocyte COX (COX1 in cortical neurons) in mammalian models 
of NVC (27, 375). Furthermore, neuronal NO based NVC regulation is known to be a 
characteristic of cerebellar neurons (376).  This points to brain region specific mechanisms of 
NVC regulation. Hence, further research is needed to investigate specificity of NO and COX 





Here I have demonstrated a non-invasive zebrafish model which can be used to further 
investigate the detailed mechanisms which underlie NVC. Similar to the mammalian system, I 
have demonstrated the existence in zebrafish of several pathways which can result in NVC, in 
particular I have demonstrated the involvement of both NOS and COX-mediated pathways.     
By avoiding the need for invasive surgery and anaesthetics (commonly used in mammalian 
models), this zebrafish model provides an opportunity to study NVC under more physiological 
conditions than mammalian. Furthermore, the ease of performing genetic manipulation makes 
zebrafish an appealing model allowing us to investigate genetic regulators of NVC. The ease 
of genetic manipulation in zebrafish would facilitate the study of the association between 
disease-related mutants and neurovascular dysfunction.   
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4 The effect of hyperglycemia on neurovascular coupling and 
function 
4.1  Aims 
In this chapter, I describe application of the NVC zebrafish model to understand the effect of 
hyperglycemia (a key component of diabetes) on NVC. I first examined the effect of 
physiologically high levels of glucose on NVC and cerebrovascular patterning. I next sought 
to determine if sodium nitroprusside, an NO donor, could rescue the effect of glucose on 
neurovascular anatomy and function. Using DAF-FM staining, I confirmed NO deficiency in 
glucose treated larvae and that this is ameliorated by SNP treatment. I next examined the effect 
of glucose with or without SNP co-treatment on different functional markers of the cells in the 
NVU, including klf2a:GFP intensity in the ECs as a marker of shear stress sensing function, 
claudin5a:GFP and sm22ab:mcherrys441 nuclei (pericytes) on the tectal vessels as a marker of 
blood brain barrier integrity. 
 
4.2  24h treatment with 20mM glucose does not affect cerebrovascular 
patterning and neurovascular coupling in 9 dpf old zebrafish 
I evaluated the effect of a glucose concentration comparable to that found in poorly controlled 
diabetes (20mM). 8 dpf larvae were immersed in 20mM glucose or mannitol for 24h followed 
by imaging of cerebrovascular anatomy and neurovascular function at 9 dpf. Representative 
micrographs comparing cerebral anatomy of mannitol and glucose treated larvae are shown in 
Figure 4-1A. Quantification of vascular anatomy (see methods section 2.4.3) showed no 
significant difference in tectal branch points, vascular length and vessel radius between larvae 





Figure 4-1: Effect of 24h glucose exposure from 8-9 dpf on cerebrovascular patterning in 
zebrafish A: Representative micrographs of cerebral vessels exposed to 20mM mannitol or glucose for 
24h (8-9 dpf). B: Square indicates region of the left optic tectum quantified in B-E. B: Number of tectal 
vessel branchpoints (n=11 larvae/group). C: Total tectal vessel length in same animals as B. D: Mean 
tectal vessel radius in same animals as in B. E: Histograms of tectal vessel radii of tectal vessels in same 
animals as in B. Scale bar represents 20 µm.  Data in A-E are mean ± s.e.m (unpaired t-test used for 




 I next examined the effect of 24h exposure to 20mM glucose from 8-9 dpf in my model of 
NVC. Neuronal calcium and RBC speed from five larvae for both glucose and mannitol treated 
groups are shown in Figure 4-2A and B, respectively. I found no significant differences 
between the glucose and mannitol treated groups, suggesting 24h glucose treatment between 




Figure 4-2: Effect of 24h glucose exposure on neurovascular function. Time series of neuronal 
activation (ΔF/Fo) and tectal vessel RBC speed in zebrafish exposed to A: 20mM mannitol and B: 
20mM glucose from 8-9 dpf (24 h) (n = 5 larvae/group). Visual stimulus is delivered for 0-8s shown by 






Figure 4-3: Effect of 24h glucose exposure on neurovascular coupling. A: Frequency of peaks of 
neuronal activation during baseline, response and recovery time periods in mannitol or glucose exposed 
larvae (n=11 larvae/group). B: RBC speed for baseline, response and recovery for same animals in A. 
C: Change in RBC speed (ΔRBC) between baseline and response time periods for the same animals as 
B. Data in A-C are mean ± s.e.m. **p<0.01, ***p<0.001(two-way ANOVA and unpaired t-test for A-
B and C, respectively). 
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4.3 120h treatment of 20mM glucose impairs cerebrovascular patterning and 
neurovascular coupling in response to light stimulation in the optic tectum 
of 9 dpf old zebrafish 
I next examined the effect of 20mM glucose for a longer duration (from 4-9 dpf). 4 dpf larvae 
were exposed to 20mM glucose and mannitol by immersion followed by imaging for 
neurovascular anatomy and function at 4.5 dpf (12h exposure), 6.5 dpf (60h exposure), 8 dpf 
(96h exposure) and 9 dpf (120h exposure). Representative micrographs are shown in Figure 
4-4. Quantification of vascular features showed significantly lesser number of branch points, 
reduced vascular length and reduced vessel radius in glucose treated group compared to 
mannitol group from 8 dpf (96h exposure) (Figure 4-5A-C). A leftward shift in the radius 
frequency histogram was observed in the glucose compared to mannitol group from 8 dpf 




Figure 4-4: Representative micrographs comparing mannitol and glucose treated larvae during 
the course of 120h (4-9 dpf) of treatment (4.5 dpf, 6.5 dpf, 8 dpf and 9 dpf).  Red box indicates the 







Figure 4-5: Effect of 120h of glucose exposure on cerebrovascular patterning during the course 
of treatment (4.5 dpf, 6.5 dpf, 8 dpf and 9 dpf). A: Number of tectal vessel branchpoints (n=17, 16, 
15 and 20 larvae for 12h, 60h, 96h and 120h exposure, respectively). B: Total tectal vessel length in 
same animals as A. C: Mean tectal vessel radius in same animals as in A. Data in A-C are mean ± s.e.m. 





Figure 4-6: A-D: Histograms of tectal vessel radii of tectal vessels in same animals as in 
Figure 4-5 (n=17, 16, 15 and 20 larvae for 12h, 60h, 96h and 120h exposure, respectively). 
Data in A-D are mean ± s.e.m.  
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I next examined the neuronal calcium and RBC speed changes in response to visual stimulation 
at 4.5 dpf, 6.5 dpf, 8 dpf and 9 dpf (Figure 4-7). There were no significant differences in 
calcium peak frequencies between glucose and mannitol treated groups at any time point 
(Figure 4-8). However, quantification of mean RBC speeds showed a lower value at each of 
the time periods (baseline, response and recovery) in the glucose compared to the mannitol 
treated group at 9 dpf (Figure 4-8). This suggests 120h of glucose treatment results in 






Figure 4-7: Time series of neuronal activation (ΔF/Fo) and tectal vessel RBC speed in zebrafish 
exposed to 20mM mannitol or glucose from 4 dpf for 12h, 60h, 96h and 120h (n=5 larvae/group). 






Figure 4-8: Effect of glucose treatment on neurovascular coupling. A: Change in neuronal calcium 
peak frequency in the left optic tectum during response compared to baseline periods (n=17, 17, 15 and 
20 for 12h, 60h, 96h and 120h exposure, respectively). B: Baseline RBC speed at the same time points 
in A & B. C: Change in RBC speed (ΔRBC) between baseline and response time periods for the same 
animals as A. Data in A-C are mean ± s.e.m. ***p<0.001, ****p<0.0001 (two-way ANOVA).  
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4.4 The nitric oxide donor (0.1mM SNP) ameliorates 20mM glucose induced 
impairment in neurovascular coupling and cerebrovascular patterning 
Various studies have shown reduced bioavailability of NO in ECs to be associated with 
diabetes. I therefore examined the effect of the NO donor SNP on NVC and cerebrovascular 
patterning. For this, I co-treated larvae with 0.1 mM SNP and glucose/mannitol from 8-9 dpf 





Figure 4-9: Mannitol/Glucose treatment with/without SNP treatment. A: Gantt chart showing the 
duration of mannitol, glucose and SNP treatment. B: Representative micrographs of cerebral vessels in 




SNP (plus mannitol) does not affect cerebrovascular patterning as shown by no statistically 
significant differences between tectal branch points, vascular length and vessel radii (Figure 4-
10A-C). However, co treatment of SNP with glucose prevented the deleterious effects on 






Figure 4-10: Sodium Nitroprusside reverses the effect of glucose exposure on cerebrovascular 
patterning. A: Quantification of number of tectal vascular branch points in all groups (n=23 
larvae/group). B: Quantification of total tectal vessel length in same animals as in A. C: Mean tectal 
vessel radius for the same animals as in A (n=23 larvae/group). D: Histogram of radii of vessels in the 
left optic tectum in the same animals as in A. Data in A-D are mean ± s.e.m. *p<0.05, **p<0.01 and 





I further quantified the effect of SNP on NVC (Figure 4-11A-D) and observed no significant 
differences in neuronal calcium between any of the groups (Figure 4-12A-B). However, 
decrease in baseline RBC speed and neurovascular uncoupling observed in glucose exposed 






Figure 4-11: Time series of neuronal activation (ΔF/Fo) and tectal vessel RBC speed in zebrafish 
(5 larvae/group) exposed to; A: 20mM mannitol for 120h from 4-9 dpf B:   20mM mannitol for 120h 
from 4-9 dpf and 0.1mM SNP for 24h from 8-9 dpf. C: 20mM Glucose for 120h from 4-9 dpf. 
D:   20mM glucose for 120h from 4-9 dpf and 0.1mM SNP for 24h from 8-9 dpf. Visual stimulus is 








Figure 4-12: Sodium Nitroprusside reverses the effect of glucose on neurovascular coupling. A: 
Frequency of peaks of neuronal activation during baseline, response and recovery time periods in 
mannitol or glucose exposed larvae with or without co-treatment with 0.1mM SNP (n=20 larvae/group). 
B: RBC speed for baseline, response and recovery for same animals in A. Data in A and B are mean ± 







4.5 20mM mannitol/glucose with or without 0.1mM SNP does not affect heart 
rate  
To assess the systemic cardiovascular effects of the treatments used I measured heart rate using 
the method described earlier (Figure 4-13). I found no statistically significant differences 
between groups treated with mannitol or glucose with/without SNP (Figure 4-13). This 







Figure 4-13: Beating heart rate quantified as beats per minute (bpm) for baseline, response and 
recovery time periods for larvae exposed to 20mM mannitol, 20mM glucose with or without SNP 





4.6 The effect of glucose with and without SNP on vascular nitric oxide 
reactivity 
Various studies have shown diabetes to be associated to reduced bioavailability of NO (377). 
Due to the transient nature of NO, dyes such as DAF-FM are used to detect NO reactivity in 
live zebrafish and cell culture (378). I thus used DAF-FM staining to examine whether glucose 
exposure reduces NO in the tectal vessels and the effect of SNP co-treatment. DAF-FM showed 
a marked reduced fluorescence intensity in the vessels in glucose-exposed compared to 
mannitol treated larvae (Figure 4-14). SNP co-treatment with mannitol has no effect compared 
to mannitol alone whereas co-treatment with glucose increases the vascular green channel 
intensity compared to glucose alone treated larvae (Figure 4-14). This confirms a reduction in 





Figure 4-14: Effect of mannitol/glucose treatment on NO reactivity, quantified by intensity of 
DAF-FM staining. A: Representative micrograph of tectal vessels showing separate and merged 
channels (green channel: DAF-FM staining, red channel: kdrl:mcherry) for 20mM mannitol or glucose 
exposed larvae co-treated with or without SNP. B: Quantification of the DAF-FM intensity in the tectal 
vessels for 20mM mannitol or glucose exposed larvae co-treated with or without SNP (n=25, 24, 27 
and 24 larvae for mannitol, mannitol + SNP, glucose and glucose + SNP, respectively). Scale bar 
represents 20 µm. Data in B is mean ± s.e.m. *p<0.05 (one-way ANOVA). 
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4.7 The effect of glucose with or without SNP treatment on klf2a: GFP reporter 
expression 
Studies have shown upregulation of endothelial klf2a by shear stress (379). Shear stress sensing 
is an important function of the ECs and is abnormal in pathologies such as atherosclerosis 
(380). However, it is not well understood if it is affected in hyperglycemia. Using 
Tg(klf2a:GFP) larvae, I repeated the same protocol of mannitol or glucose exposure with or 
without SNP co-treatment. Glucose exposure reduced klf2a:GFP intensity compared to 
mannitol (Figure 4-15). Co-treatment with SNP and glucose restored klf2a:GFP intensity 
(Figure 4-15). Since it is not known if NO could modulate expression of klf2a, this suggests 
the effect of SNP in recovering the expression could be secondary to its effect on RBC speed. 




Figure 4-15: Effect of mannitol/glucose treatment with/without SNP on expression of klf2a:GFP 
expression. A: Representative micrograph of tectal vessels in Tg(klf2a:GFP) exposed to 20mM 
mannitol or glucose co-treated with or without SNP. B: Quantification of the klf2a:GFP intensity in the 
tectal vessels for 20mM mannitol or glucose exposed larvae co-treated with or without SNP (n=26 




4.8 The effect of glucose with or without SNP treatment on claudin5a: GFP 
reporter expression  
Multiple reports have shown BBB to be affected in ageing and dementia (381, 382). Few 
studies have also shown BBB pathologies in diabetes (383). I therefore tested the effect of 
glucose exposure on BBB permeability using a novel transgenic zebrafish model expressing 
claudin5a as a marker of BBB development (326). Representative micrographs of 
Tg(claudin5a:GFP;kdrl:HRAS-mcherry) are shown in Figure 4-16. Similarly to the klf2a 
reporter, glucose exposure reduced vascular claudin5a:GFP expression which was restored by 




Figure 4-16: Effect of mannitol/glucose treatment with/without SNP treatment on claudin5a:GFP 
expression. A: Representative micrograph of tectal vessels showing separate and merged channels 
(green channel: claudin5a:GFP, red channel: kdrl:mcherry) for 20mM mannitol or glucose exposed 
larvae co-treated with or without SNP. B: Quantification of the claudin5a:GFP intensity in the tectal 
vessels for 20mM mannitol or glucose exposed larvae co-treated with or without SNP (n=21,20,18 and 
23 larvae for mannitol, mannitol + SNP, glucose and glucose + SNP, respectively). Scale bar represents 




4.9 Glucose exposure reduced the number of sm22ab:mcherrys441 labelled nuclei 
on the tectal vessels which was restored by SNP co-treatment 
Smooth muscle cell protein 22 (sm22) is known to be expressed in contractile mural cells (384). 
Pericytes have been shown to be contractile and to express smooth muscle cell actin and desmin 
(385). As discussed in chapter 1, few studies have demonstrated increased pericyte migration 
in diabetes (79) and recent advances have shown pericytes to be involved in NVC (82). Since 
I observed neurovascular uncoupling in glucose exposed larvae, I therefore examines pericyte 
function in zebrafish with mannitol/glucose with or without SNP co-treatment. Pericytes are 
not well characterised in zebrafish. Using a novel transgenic line developed by Dr. Rob 
Wilkinson, Tg(sm22ab:mcherrys441) I quantified the number of mural cells (pericytes/VSMCs) 
on the tectal vessels (480 x 360 x 54 µm3) in embryos exposed to glucose or mannitol with or 
without co-treatment with SNP. Glucose exposure induced a statistically significant reduction 
in the sm22ab:mcherry s441 labelled nuclei on the tectal vessels suggesting a reduction in the 




Figure 4-17: Effect of mannitol/glucose treatment ± SNP on mural cell count on the tectal vessels. 
A: Representative micrograph of tectal vessels showing separate and merged channels (green channel: 
fli1:GFF:UAS:GCaMP6f, red channel: sm222ab:mcherry s441) for 20mM mannitol or glucose exposed 
larvae co-treated with or without SNP. B: Quantification of the number of sm22ab:mcherrys441 nuclei 
on the tectal vessels for 20mM mannitol or glucose exposed larvae co-treated with or without SNP 





4.10 The effect of glucose with or without SNP treatment on iGluSnFr reporter 
intensity 
Multiple reports have suggested zebrafish possess radial glial cells with astrocyte-like 
characteristics such as presence of glutamate transporters and aquaporin channels (314, 386) 
as described earlier (section 1.13.2). The role of glial cells in NVC is still under debate however 
there are studies suggesting in mammalian models suggesting glial dysfunction in diabetes (as 
discussed in section 1.6.3). I therefore sought to examine the effect of glucose exposure on 
astroglial structures in 9 dpf old zebrafish. Using a novel transgenic line that indicates glial 
glutamate signalling by expressing iGluSnFR driven by GFAP, I quantified intensity of 
iGluSnFR in the teO of zebrafish larvae exposed to mannitol or glucose with or without SNP 
treatment (Figure 4-18A). Glucose exposure induced a statistically significant reduction of 
iGluSnFR intensity in the teO compared to mannitol (Figure 4-18B). Co-treatment with SNP 




Figure 4-18: Effect of mannitol/glucose treatment on GFAP:iGluSnFR intensity in the tectum. A: 
Representative micrograph of optic tectum in Tg(GFAP:iGluSnFR) for 20mM mannitol or glucose 
exposed larvae co-treated with or without SNP. B: Quantification of iGluSnFR intensity in the optic 
tectum for 20mM mannitol or glucose exposed larvae co-treated with or without SNP (n=32,30,28 and 
29 larvae for mannitol, mannitol + SNP, glucose and glucose + SNP, respectively). Scale bar 20µm. 
Data in B is mean ± s.e.m. ***p<0.001, ****p<0.0001 (one-way ANOVA). 
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Glutamine synthetase (GS) is an astroglial-specific enzyme which converts glutamate released 
by neurons to glutamine (386, 387). Using IHC, I examined the effect of glucose exposure with 
or without SNP on expression of GS in the teO of 9 dpf old zebrafish. Glucose exposure 
reduced expression of GS compared to mannitol (Figure 4-19 and Figure 4-20). Co-treatment 
of SNP with mannitol had no effect however co-treatment of glucose with SNP increases the 
tectal expression of GS compared to glucose alone (Figure 4-20 and Figure 4-21B). The 
mechanisms by which increasing NO could improve glial function are not known.  
 
4.11 The effect of glucose with or without SNP treatment on TRPV4 and 
glutamine synthetase expression  
Since hyperglycemia has been shown to downregulate TRPV4 in the ECs of the retinal 
microvasculature (259). I investigated TRPV4 expression by immunohistochemistry in 9 dpf 
old zebrafish larvae exposed to glucose or mannitol with or without SNP treatment. I performed 
immunohistochemistry with combined antibodies for glutamine synthetase (as described in the 
previous section) to first compare expression patterns in the teO. Glucose exposure decreased 
overall TRPV4 expression in the tectum (which could include radial glial, endothelial and 
neuronal expression of TRPV4) compared to mannitol exposed larvae (Figure 4-20A). A 
similar reduction was observed in the glutamine synthetase expression (Figure 4-20B). 
Further, co-treatment of glucose exposed larvae with SNP lead to an increase in the TRPV4 
and glutamine synthetase expression in the teO compared to glucose only treated larvae 




Figure 4-19: Representative micrographs of optic tectum showing the effect of mannitol/glucose 
treatment with/without SNP treatment on the expression of glutamine synthetase (red channel) 




Figure 4-20: Effect of mannitol/glucose exposure on the glutamine synthetase and TRPV4 
expression in tectum. Quantification of A:  TRPV4 and B: glutamine synthetase expression in the 
optic tectum in mannitol/glucose exposed larvae co-treated with/without SNP (n=24, 25, 21 and 27 
larvae for larvae for mannitol, mannitol + SNP, glucose and glucose + SNP, respectively). Data in A 





4.12 The effect of glucose with or without SNP treatment on GFAP expression  
Experimental studies have shown reduction in glial function with hyperglycemia and type 1 
diabetes, particularly astrogliosis (indicated by over-expression of GFAP) (388). I therefore 
examined GFAP expression by immunohistochemistry in mannitol or glucose treated animals 
with or without SNP treatment. Representative micrographs of whole mount 9 dpf old zebrafish 
stained for GFAP and DAPI are shown in Figure 4-21. Glucose exposure increased GFAP 
expression compared to mannitol, quantified by mean intensity of red fluorescence in the teO 




Figure 4-21: Representative micrographs showing the effect of mannitol/glucose exposure 
with/without SNP treatment on GFAP expression (red channel: GFAP and blue channel: 




Figure 4-22: Quantification of GFAP expression in the optic tectum in mannitol/glucose exposed 
group with/without SNP treatment (n=16, 12, 18 and 20 larvae for larvae for mannitol, mannitol 








4.13 The effect of glucose with or without SNP treatment on locomotion and 
light/dark preference  
In the previous sections, I described various functional and anatomical defects in the NVU 
induced by glucose exposure and show that SNP is largely able to rescue these. I next examined 
the effect of glucose exposure on locomotion and behaviour in 9 dpf old zebrafish larvae. Using 
viewpoint system for larval tracking (as described in section 2.8), I first tested for light-dark 
preference in mannitol or glucose exposed larvae with or without co-treatment with SNP. 
Figure 4-23 shows the trajectories of four representative zebrafish larvae for a period of 1 h in 
each treatment group. Red and green colours mark the high and low speed locomotion, 
respectively (as described in section 2.8). I tested the light dark preference using two measures; 
percentage of time spent in light and dark side of the well and the ratio of time spent in light vs 
dark (L/D ratio). Mannitol exposed larvae at 9 dpf showed a preference for light, spending 
~80% time in the light and ~20% time in dark (Figure 4-24A). Glucose exposure reduced this 





Figure 4-23: Representative trajectories of 9 dpf old zebrafish moving in half darkened wells (of 
a 12 well plate) as tracked by Viewpoint software for mannitol or glucose with or without SNP 
treatment. Red trajectories represent high speed locomotion (> 64 mm/s), green represents low speed 











Figure 4-24: Quantification of time spent by zebrafish larvae in light and dark sides of the wells. 
A: Percentage of time spent in light and dark regions of the well by larvae exposed to mannitol or 
glucose with or without SNP (n = 50, 45, 44 and 56 larvae for mannitol, mannitol+SNP, glucose and 
glucose+SNP, respectively). B: Light/Dark (L/D) ratios for the same animals as in A. Data in A and B 
are mean ± s.e.m. *p<0.05 (one-way ANOVA). 
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I further investigated the effect on glucose with/without SNP exposure on the time spent in 
inactivity, low speed and high speed locomotion, in both light and dark regions of the well. I 
found a significant increase in the time spent in both the low and high speed locomotion in the 
glucose exposed larvae in the light region of the well with an associated reduction in the time 
spent inactive (Figure 4-25). SNP co-treatment reversed this effect (Figure 4-25). Quantifying 
the time spent in inactivity, I found the glucose exposed larvae show reduced inactivity 
compared to mannitol exposed larvae (Figure 4-25) and that co-treatment with SNP increased 
the inactivity similar to that observed in the mannitol exposed larvae (Figure 4-25). 
Quantifying the same measures for the dark region of the well, I found similar trends to that 







Figure 4-25: Quantification of percentage time spent in inactivity, low and high speed locomotion 
in the light region by the same animals as in Figure 4-24 (n = 50, 45, 44 and 56 larvae for mannitol, 
mannitol+SNP, glucose and glucose+SNP, respectively). Data is mean ± s.e.m. *p<0.05, **p<0.01, 





Figure 4-26: Quantification of percentage time spent in inactivity, low and high speed locomotion 
in the dark region by the same animals as in Figure 4-25 (n = 50, 45, 44 and 56 larvae for mannitol, 
mannitol+SNP, glucose and glucose+SNP, respectively). Data is mean ± s.e.m. *p<0.05, **p<0.01, 








4.14 Increase in the baseline neuronal calcium activity with glucose treatment is 
normalized by co-treatment with SNP 
Various clinical and experimental studies have shown associations between hyperglycemia and 
seizures (389). There are no precise mechanisms described as to how hyperglycemia or any 
diabetes pathology could result in neuronal hyperexcitability. I therefore tested the occurrence 
neuronal calcium peaks without any light stimulation to observe baseline neuronal firing 
activity. Representative time series of baseline neuronal firing in larvae exposed to mannitol or 
glucose with or without SNP quantified as ΔF/Fo are shown in Figure 4-27A. I found glucose 
exposure increased baseline firing activity compared to mannitol (Figure 4-27B).  Co-
treatment with SNP and glucose reduced neuronal calcium peak frequency compared to 
glucose alone (Figure 4-27B). This suggests NO could be also a key factor in modulating the 




Figure 4-27: Effect of mannitol/glucose treatment with/without SNP on baseline neuronal calcium 
peak frequency. A: Time series of neuronal activation (ΔF/Fo in zebrafish (5 larvae/group) exposed to 
(left: top to bottom); 20mM mannitol for 120h from 4-9 dpf, 20mM mannitol for 120h from 4-9 dpf 
and 0.1mM SNP for 24h from 8-9 dpf, 20mM Glucose for 120h from 4-9 dpf and 20mM glucose for 
120h from 4-9 dpf and 0.1mM SNP for 24h from 8-9 dpf. B: Quantification of neuronal calcium peak 
frequency for each of the groups (n=28 larvae/group). Data is mean ± s.d. in A and mean ± s.e.m. 







Kim et al., (160) proposed that vascular tone can decrease neuronal firing through astrocyte 
TRPV4 activation, thereby suggesting a way of vascular control of neuronal activity. I have 
described earlier the glucose exposure decreases the vessel thickness (section 4.3), RBC speed 
(section 4.3) and TRPV4 expression (section 4.12). This suggests that the increase in neuronal 
calcium peak frequency induced by glucose exposure could also be associated with a decrease 
in TRPV4 expression, on the lines of vasculoneuronal coupling (160). To investigate if 
increases in neuronal firing could be mediated by TRPV4, I quantified neuronal calcium peak 
frequency with and without treatment with a TRPV4 antagonist III (24 h treatment). 
Representative time series of neuronal firing in controls (E3) and TRPV4 antagonist treated 
larvae are shown in Figure 4-28A. I found larvae exposed to the TRPV4 antagonist had 
statistically significant higher neuronal calcium peak frequency (Figure 4-28) similar to 




Figure 4-28: Effect of 24h treatment of TRPV4 antagonist on baseline neuronal calcium peak 
frequency. A: Time series of neuronal activation (ΔF/Fo) in zebrafish (5 larvae/group) in vehicle (E3) 
and exposed to TRPV4 antagonist III for 24h from 8-9 dpf. B: Quantification of neuronal calcium peak 




In this chapter I described application of the model of NVC developed in Chapter 3 to 
hyperglycemia (an important pathology of diabetes). Exposing zebrafish larvae to 20 mM 
glucose (levels seen in poorly controlled diabetes) from 8-9 dpf did not affect either NVC or 
cerebrovascular patterning. However, with glucose exposure from 4-9 dpf, I found a reduction 
in baseline RBC speed, neurovascular uncoupling and cerebrovascular patterning defects. I 
performed DAF-FM staining on groups exposed to mannitol or glucose and found a decrease 
in the staining with glucose treatment compared to mannitol exposed group. All these effects 
were ameliorated by 24 h treatment with the NO donor, SNP (that increased NO reactivity by 
DAF-FM staining), suggesting the potential for NO as a therapeutic strategy for diabetes and/or 
hyperglycemia related neurovascular dysfunction. To further understand the mechanism of 
action of SNP in restoring NVC, I investigated the effect of glucose exposure with or without 
SNP on different cell types within the NVU such as ECs, pericytes and radial glial cells. Overall 
I observed decreases in klf2a:GFP expression (EC marker), claudin5a:GFP expression (EC 
marker and representative of blood brain barrier permeability), reduction in the number of 
sm22ab:mcherrys441 nuclei (pericytes on the tectal vessels), reduction in glutamine synthetase 
(marker of glutamate uptake by the radial glial cells), increase in GFAP expression (marker of 
reactive astroglial cells) and overall decrease in TRPV4 expression in the teO. This suggests 
the neurovascular uncoupling observed with glucose exposure is accompanied by defects in 
various cells in the NVU suggesting involvement of these cells in mediating the NVC. Further, 
co-treatment of glucose exposed animals with SNP corrected all these defects confirming the 
importance and multiple downstream targets of NO in the NVU. Some of these observations 
are supported by the literature (section 1.6), however I here present a comprehensive 
description of the defects induced by glucose exposure. I have further described reduced dark-
light preference and increased locomotion in 9 dpf old zebrafish larvae exposed to glucose. 
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Light/Dark preference is generally used as a measure for unconditioned anxiety and related 
disorders in rodents and zebrafish (390, 391). Unconditioned anxiety is influenced by 
environmental, emotional and cognitive factors (391, 392). It is based on an 
approach/avoidance conflict between the drive to explore novel area and an aversion to brightly 
lit/completely dark open spaces (393). The approach/avoidance conflict is a well-studied 
behaviour in mammals and is known to have various neural substrates in the brain such as the 
limbic system, anterior cingulate cortex, ventral striatum and prefrontal cortex (393). Although 
zebrafish do not possess a cortex, they have Vd/Dm as the homologous structures to 
mammalian amygdala and striatum (described in section 1.11.1). Thus impaired light/dark 
preference could imply an abnormal circuitry in the zebrafish Vd/Dm. Anatomical studies with 
zebrafish have shown that Vd/Dm project to the teO and hence any defects in the Vd/Dm 
circuitry could also affect the teO. Hyperglycemia induced changes in the light/dark preference 
shown in this thesis could suggest that impaired NVC in teO possibly leading to circuitry 
defects between teO and other brain areas such as Vd/Dm involved in choice preference. 
Furthermore, increased baseline neuronal calcium peak frequency observed in glucose exposed 
larvae could support the finding of increased locomotion in response to hyperglycemia. 
Radial glial cells are speculated to be an early form of stellate astrocytes found in mammalian 
species and hence could share few to several functionality of the mammalian astrocytes (320).  
Furthermore, there are studies showing their role in glutamate recycling from the extra synaptic 
space (394). Hence any abnormal calcium signalling following glucose exposure could also 
affect other functions of these cells, including uptake of glutamate as what I have shown with 
immunostaining with glutamine synthetase antibodies post glucose exposure. Further this 
speculated abnormal glutamate uptake could result in accumulation of glutamate in the 
extrasynaptic space leading to possible recurrent neuronal depolarization, i.e., increase in 
baseline neuronal firing. This fits with the observation of increased number of calcium peaks 
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observed post glucose treatment. Neuronal hyperexcitability and increased firing is known to 
be associated to the seizures, commonly observed in diabetic patients. Hence the various 
cellular markers shown here to be affected by the glucose exposure could explain this 
observation of higher predisposition of the diabetic patients to epileptic episodes or seizures. 
Further increased neuronal firing could also lead to abnormal and non – precise pre and post 
synaptic neuronal firing causing possible defects in the synaptic plasticity mechanisms 
necessary to bring about cognition and memory. Further exploration of this could help us 
understand the relation between diabetic pathology and underlying reasons for the observation 
of cognitive defects observed in the patients. Further this theory qualitatively fits the notion 
suggesting diabetes to be a risk factor for dementia and neurodegenerative disorders.   
 
4.16 Conclusions 
Previous studies have linked hyperglycemia and pharmacologically induced diabetes to 
reduction in cerebral blood flow. However, this is the first such study in zebrafish and the first 
in any model demonstrating that SNP reverses these negative consequences.  
The rescuing effect of NO on the all the NVC and anatomical cellular parameters studies 
suggests a possible way to treat diabetes associated neurovascular dysfunction. With emerging 
evidences about increased importance of NO in NVC, this seems pragmatic as NO is not only 
important signalling molecule to mediate NVC but also important in mediating endothelial 
function and vascular tone (395). Hence, the rescuing effect of NO further impinges on the 
importance on maintaining endothelial and therefore vascular health for normal brain function. 
Future studies are needed to corroborate if these effects of glucose exposure and NO donors 
are seen even in mammalian models and also possibly explaining the trigger effect of the drug 
SNP. With the multifaceted data presented here demonstrating the importance of NO in 
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maintaining neurovascular function and vascular health, it seems imperative to further explore 
the precise mechanisms of actions of SNP and possibly other NO donors. All these are 
necessary to push forward the idea of the use of NO based therapeutics for the treatment of 
diabetes and even for targeting disorders associated with neurovascular uncoupling and low 




5 Effect of gch1 mutation on neurovascular coupling and 
cerebrovascular patterning 
 
5.1  Aims  
In this chapter I study NVC in a novel gch1 mutant line generated by Dr. Marcus Keatinge. 
GCH1 is an enzyme called GTP cyclohydrolase 1, required in the first three steps in production 
of tetrahydrobiopterin (BH4). BH4 is involved in physiological processes including production 
of neurotransmitters such as dopamine and serotonin (396). Lack of dopamine is a hallmark of 
prominent neurodegenerative diseases such as Parkinson’s disease. In humans, gch1 mutations 
are associated with Dopa-responsive dystonia and parkinsonism (397, 398). 
 
5.2 Cerebrovascular patterning is affected in homozygous mutants (gch1(-/-)) 
compared to wild type (gch1(+/+)) and heterozygous mutants (gch1(+/-)) 
I first assessed the effect of the homozygous gch1 mutation on cerebrovascular anatomy. 
Representative micrographs for the anatomy from gch1(+/+), gch1(+/-) and gch1(-/-) are 
shown in Figure 5-1. I observed reduced branchpoint number and vascular length in gch1(-/-) 
compared to gch1(+/+) and gch1(+/-) (Figure 5-2A-B). Mean vessel radius in the gch1(-/-) 
was lower compared to gch1(+/-) while it was not statistically different from the gch1(+/+) 
(Figure 5-2C). Radius frequency histograms for all the three groups are shown in Figure 5-2D.  
All these results demonstrate a deleterious effect of the homozygous gch1 mutation on the 




Figure 5-1: Representative micrographs of tectal vessels in wildtype (gch1(+/+)), heterozygous 
(gch1(+/-)) and homozygous gch1 mutants (gch1(-/-)).  Box indicates the region of the left optic 
tectum quantified for vascular features (branchpoints, tectal vascular length and vessel radius). Scale 




Figure 5-2: Effect of gch1 mutation on cerebrovascular patterning. A: Number of tectal vessel 
branchpoints (n=18,17,17 for gch1(+/+), gch1(+/-) and gch1(-/-), respectively). B: Total tectal vessel 
length in same animals as A. C: Mean tectal vessel radius in same animals as in B. D: Histograms of 
tectal vessel radii of tectal vessels in same animals as in A. Data in A-D are mean ± s.e.m. *p<0.05, 








5.3 Neurovascular coupling in impaired in homozygous mutants (gch1(-/-))  
Embryos were first genotyped at 3 dpf as wild types (gch1(+/+)), heterozygous (gch1(+/-)) or 
homozygous mutants (gch1(-/-)). NVC in response to 8 seconds light stimulation was then 
assessed as described in section 2.2. Representative time series for five larvae for change in 
neuronal calcium fluorescence in the teO and RBC speed in the tectal vessels for gch1(+/+), 
gch1(+/-) and gch1(-/-) are shown in Figure 5-3A-B. I found no significant differences in 
neuronal calcium peak frequency between the groups (gch1(+/+), gch1(+/-) and gch1(-/-)) 
(Figure 5-4A). However, I found gch1(-/-) to have reduced baseline blood flow and change in 
in RBC speed in response to visual stimulation compared to gch1(+/+) and gch1(+/-) larvae 




Figure 5-3: Time series of neuronal activation (ΔF/Fo) and tectal vessel RBC speed in A: 
gch1(+/+), B: gch1(+/-) and C: gch1(-/-) (n=5 larvae/group). Visual stimulus is delivered for 0-8s 





Figure 5-4: Effect of gch1 mutation on neurovascular coupling. A: Frequency of peaks of neuronal 
activation during baseline, response and recovery time periods in gch1(+/+) (n=19 larvae), gch1(+/-) 
(n=19 larvae) and gch1(-/-) (n=23 larvae). B: RBC speed for baseline, response and recovery for same 




5.4 Behavioural measurements of locomotion show reduction in total movement 
in homozygous gch1(-/-) mutants  
 
Using Viewpoint zebrabox, the motion of all the three groups: gch1(+/+), gch1(+/-) and gch1(-
/-) was assessed. Movement was tracked for 30 minutes with a sampling time of 1 minute.  
Distance moved was analysed for high (speed>64 mm/s) and low (64 mm/s>speed>30 mm/s) 
speed locomotion (as described in section 2.8). Representative trajectories for gch1(+/+), 
gch1(+/-) and gch1(-/-) are shown in Figure 5-5A with low speed (3-6mm/s) trajectories 
marked in red and high speed (>64 mm/s) trajectories marked in green. I calculated the mean 
distance travelled at these two speed limits for each of the gch1(+/+), gch1(+/-) and gch1(-/-) 
and found that both slow and high speed movement in gch1(-/-) are significantly reduced 




Figure 5-5: Effect of gch1 mutation on locomotion in 8 dpf zebrafish. A: Representative trajectories 
of gch1(+/+), gch1(+/-) and gch1(-/-) siblings (n=4 larvae/group). B: Quantification of mean distance 
moved with low speed (30-60 mm/s) by gch1(+/+) (n=21 larvae), gch1(+/-) (n=16 larvae) and gch1(-
/-) siblings (n=19 larvae). C: Quantification of mean distance covered with high speed by the same 







5.5 Administration of SNP ameliorates cerebrovascular patterning defects in 
gch1(-/-) mutants 
I next assessed the effect of SNP on the cerebrovascular patterning defects observed in gch1(-
/-). Here, I have compared the cerebrovascular patterning in gch1(+/+) and gch1(-/-) with or 
without 0.1 mM SNP treatment (from 7-8 dpf for 24 h). Representative micrographs are shown 
in Figure 5-6. SNP treatment ameliorated the effect of gch1 mutation on branch point and 
vascular length (Figure 5-7A-B). I did not observe statistically significant differences in vessel 




Figure 5-6: Representative micrographs of cerebral vessels of 8 dpf gch1(+/+), gch1(-/-) siblings 
with or without SNP treatment. Square indicates region of left optic tectum quantified for various 





Figure 5-7: SNP rescues the deleterious effects of gch1 mutation on the cerebrovascular 
patterning. A: Number of tectal vessel branch points for gch1(+/+) and gch1(-/-) siblings with or 
without SNP (n=16 larvae/group). B: Total tectal vessel length in same animals as A. C: Mean tectal 
vessel radius in same animals as in A. D: Histograms of tectal vessel radii of tectal vessels in same 






5.6 Administration of SNP rescues neurovascular coupling in gch1(-/-) 
As described earlier, gch1 is a key catalyst in the synthesis of BH4 which is also important for 
NO synthesis. Since SNP was shown to ameliorate all the glucose induced deficits on the NVC, 
I tested the effect on neurovascular dysfunction in gch1(-/-). Representative time series for five 
larvae for change in neuronal calcium fluorescence in the teO and RBC speed in the tectal 
vessels for gch1(-/-) and gch1(-/-) with or without SNP are shown in Figure 5-8. I found that 
overnight treatment with 0.1mM SNP did not affect the neuronal activation in response to red 
light stimulation (Figure 5-9A) however it rescued the increase in red blood cell speed, and 






Figure 5-8: Time series of neuronal activation (ΔF/Fo) and tectal vessel RBC speed in A: 
gch1(+/+), B: gch1(-/-) C: gch1(+/+) + SNP and D: gch1(-/-) + SNP (n=5 larvae/group). Visual 





Figure 5-9: SNP rescues the neurovascular coupling defects in gch1 mutants. A: Frequency of 
peaks of neuronal activation during baseline, response and recovery time periods in gch1(+/+) and 
gch1(-/-) with or without co-treatment with 0.1mM SNP (n=20 larvae/group). B: RBC speed for 
baseline, response and recovery for same animals in A. Data in A and B are mean ± s.e.m. *p<0.05, 




5.7 Co-treatment of homozygous gch1 mutants with SNP rescues the movement 
defects. 
I then assessed the effect of SNP treatment on the locomotion of gch1(-/-) using Viewpoint-
zebrabox with the protocol described earlier. Representative motion trajectories for gch1(+/+) 
and gch1(-/-) with or without SNP treatment are displayed in Figure 5-10A. I found that total 
distance moved by gch1(-/-) treated with SNP was significantly higher than gch1(-/-) only 
group of larvae (Figure 5-10B-C). This suggests NO donors could be a potential strategy to 




Figure 5-10: SNP rescues locomotion defects in gch1 mutants. A: Representative trajectories of 
gch1(+/+) and gch1(-/-) siblings with or without SNP treatment (n=4 larvae/group). B: Quantification 
of mean distance moved with low speed (3-6 mm/s) by gch1(+/+), gch1(-/-) with or without SNP (n=36 
larvae/ group). C: Quantification of mean distance covered with high speed by the same animals as in 
B. Data in B and C are mean ± s.e.m. *p<0.05, **p<0.01, ***p<0.001 (one-way ANOVA). 
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5.8 gch1 mutants display increased NO reactivity which is reduced by co-
treatment with SNP 
NOS requires BH4 as an essential cofactor for NO synthesis (399), and production of BH4 is 
dependent on gch1 (400). I used the DAF-FM staining protocol to test the NO reactivity in the 
homozygous gch1 mutants with or without SNP treatment. Representative micrographs of the 
tectal vessels stained with DAF-FM in gch1(+/+), gch1(-/-) with or without SNP are shown in 
Figure 5-11 . I found that homozygous gch1 mutants showed significantly increased DAF-FM 
intensity compared to wild type siblings (Figure 5-12). Treatment of homozygous gch1 
mutants with SNP significantly decreased the intensity of the DAF-FM staining compared to 
untreated gch1 mutant larvae (Figure 5-12). This is contrary to what was observed in the 
glucose exposed group co-treated with or without SNP in the chapter 5. Studies have shown 
that DAF-FM stain could possibly also stain reactive NO species (RNOS) other than NO only 
(401). While I have shown homozygous gch1 mutants to have a similar neurovascular 
uncoupling phenotype to that of glucose exposed groups, homozygous mutants are lethal and 
do not survive past 10-15 days. In the light of these observations, it could be hypothesized that 
a moderate decrease in nNOS and/or eNOS could show a decrease in NO reactivity observed 
by DAF-FM staining (as shown in glucose exposed larvae in chapter 5). A complete loss of 
NO due to lack of essential enzyme for NO production (as seen in homozygous gch1 mutants) 
could lead to a compensatory increase in iNOS (which is also associated to inflammatory 
phenotype and thus production of RNOS, (402)) causing non-specific DAF-FM staining. 
Furthermore, NO supplementation through SNP could provide a feedback signal and contribute 
to the decrease in reactive nitrite species non-specifically stained by DAF-FM in homozygous 




Figure 5-11: Representative micrographs of tectal vessels stained for NO reactivity with DAF-FM 




Figure 5-12: Quantification of DAF-FM staining in the tectal blood vessels in gch1(+/+) and gch1(-
/-) siblings co-treated with without SNP (n =14, 13, 13 and 10 for gch1(+/+) and gch1(-/-) siblings 

















In this chapter I have shown the effect of a novel mutation in the enzyme (gch1) responsible 
for synthesis of an essential cofactor (BH4) for the production of various neurotransmitters 
(such as dopamine and serotonin) and NO (396, 399). Recent studies have linked this gene with 
disorders associated with dopamine deficiency such as Parkinson’s disease (397). Using the 
novel zebrafish model of NVC described in chapter 3, I have characterized neurovascular 
function (NVC and cerebrovascular patterning) in larvae with homozygous gch1 mutation. I 
found that homozygous gch1 mutants had impaired cerebrovascular patterning evidenced by 
reduced number of branch points and total vascular length. I further demonstrated that these 
anatomical defects found in the homozygous mutants are associated with neurovascular 
uncoupling and that despite having preserved neuronal responses to visual stimulation, the 
expected increase in RBC speed in response to the stimulus is not observed. The similarity 
between this observation and the effects of glucose exposure is interesting as it points to 
possible commonalities between neurological disorders such as Parkinson’s disease and 
vascular disorders such as diabetes. I have also found that locomotion in the homozygous gch1 
mutants is reduced compared to wild type siblings and heterozygous gch1 mutants. 
Given the similarity in phenotype between the gch1 mutants and larvae exposed to glucose, I 
tested the effect of SNP which had rescued the effect of glucose in the previous chapter. 
Excitingly, I found that treating homozygous gch1 mutants with SNP rescued all the 
cerebrovascular patterning defects, recovered the NVC and improved the impairment in 
locomotion in homozygous mutants, suggesting NO is important to maintain brain function. 
5.10  Conclusion and future work 
From the observations of the effects of homozygous mutation on the cerebrovascular patterning 
and NVC, I have hereby shown the importance of NO and NVC in maintaining brain health. 
While here the gch1 mutation is a global mutation, previous evidence points to a link between 
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endothelial specific mutation in gch1 and development of Parkinson’s disease (403, 404).  In 
general, this and the previous chapter imply there are shared mechanisms between neurological 
disorders and vascular disorders such as diabetes. This calls for further research on the common 
factors between the two genres of the diseases. This is important to understand if diabetes and 
other cardiovascular abnormalities could be used as early prognostic markers for neurological 
diseases. Further work is needed to understand the effect of giving NO donors to gch1 mutants 
and possible target effects of the drug on functionality of various cells in the NVC. The data 
on locomotion shown in this work suggest further investigation into the effects on cognitive 
function and memory in these mutants with or without drug treatments is warranted. This might 
support development of potential NO based drug therapies for treatment of cognitive disorders. 
Further work is also needed to test the specificity of SNP on the rescuing effect to see if this is 
solely mediated by SNP or is a general effect of any NO donor, such as isosorbide mononitrate. 
Studies with rodent endothelial specific gch1 have shown various cardiovascular abnormalities 
in the animals further emphasizing the link between cardiovascular and neurological diseases. 
All these evidences together provide a framework to be tested in higher model organisms in 
order to take it to the translational scale in future. In general, these data suggest the importance 
of NVC in the brain and that impaired NVC could lead to a plethora of diseases affecting the 





6 Computational model of neurovascular unit simulating 
hyperglycemic neurovascular uncoupling 
 
6.1 Aims  
 
In this chapter, I aimed to develop a computational model of the NVU in order to simulate 
NVC in normal glucose conditions ([glucose]
blood
 =5 mM) and describe the stimulus evoked 
increased in the neuronal activity, followed by vasodilation. Each compartment of the model 
(neuron, astrocyte and blood vessel) is modelled such that stimulating neurons leads to release 
of neuronal glutamate as an input to the astrocyte. The astrocyte is modelled to increase 
intracellular calcium in response to this neuronal glutamate to release vasodilator (338) EET 
onto a lumped blood vessel compartment. This blood vessel compartment comprises NO 
coupled to vessel diameter and modelled to represent both capillary/arteriolar dilation 
(depending on the parameters, δ and ω, see section 2.10.3).  To simulate the effect of 
hyperglycemia ([glucose]
blood
 >15 mM), I developed equations to simulate blood NO levels, 
governed by vasodilatory signals (EET) arising from NVC dependent on the modelled values 
of blood glucose (section 2.10.3).   
Using the vascular feedback through TRPV4 on astrocytes computational model developed by 
Kenny et al. (338), I extended the vascular feedback to neurons via release of adenosine by 
astrocytes (160).  Combining this with the model of hyperglycemia, I attempted to explain the 
observed effects of hyperglycemia on neuronal activity in my experimental work (section 4.3) 
and to predict the consequences on synaptic plasticity mechanisms such as spike time 
dependent plasticity (STDP) (described in section 1.12.2). I used a standard STDP kernel to 
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examine whether hyperglycemia might affect synaptic learning (a computational correlate of 
memory). 
 
6.2 A minimal model of the neurovascular unit displays neurovascular coupling  
 
The models used in this chapter are described in section 2.10. A schematic representation of 
the three compartments with the modelled parameters is shown in Figure 6-1A.  I simulated 
the neuronal spiking in response to 8s stimulation as an input to the neuronal compartment. 
Random Gaussian noise was added to the stimulation pulse to make this more realistic (Figure 
6-1B). Simulations produced using this model showed prominent spikes in response to 
stimulation and a corresponding increase in quantal release of glutamate from the neuron 
(Figure 6-1C-D). Furthermore, a prominent [Ca2+]i response was observed in the astrocyte 
compartment (Figure 6-2C), followed by EET release (Figure 6-2D) and an increase in the 
positive current through TRPV4 (I
TRPV4
) (Figure 6-2E). EET was modelled in the present study 
rather than prostaglandins to most of the computational modelling literature focussed on EET 
but will be a prospective direction (discussed in chapter 7). 
Using the equations developed for vasodilator mediated release of NO by ECs (section 2.10.3), 
a prominent NO pulse (of 3 µM) was observed in the vessel compartment (as a result of 
activation of ECs) (Figure 6-3C), followed by an increase in vessel diameter (Figure 6-3D). 
All simulations of NVC were performed with glucose values set to 5mM (as found in 
normoglycemic humans and zebrafish (405, 406)). The peaks in neuronal membrane voltage 
and vessel dilation (as measured by changes in vessel diameter) were predicted to be 6-10 
seconds apart (~10 s from first neuronal peak and ~6 s from the second neuronal peak), similar 






Figure 6-1: Neuronal compartment dynamics in response to an 8s stimulation with 5mM 
[glucose]
blood
.  A: Schematic representation of computational model of neurovascular unit showing the 
neuron (N), astrocyte (A) and blood vessel (V) compartment. Neuron upon stimulation with external 
current (Iext) releases glutamate (Glut), activating the astrocyte which the releases EET, causing 
vasodilation and increases in endothelial cell (EC) derived NO. Vasodilation sends feedback to 
astrocyte through TRPV4 activation that causes inhibition of neuronal firing through astrocyte derived 
adenosine. B: Stimulation signal (Iext) input to the neuron, modelling the experimental 8s stimulation 
protocol. Random Gaussian noise was added to make it experimentally realistic. C: Neuronal spiking 
output of the modified HH neuron model. D: Modelled glutamate (Glut) release in response to neuronal 




Figure 6-2:Astrocyte compartment dynamics in response to 8 s stimulation with 5mM 
[glucose]
blood
. A: Schematic representation of computational model of neurovascular unit showing the 
neuron (N), astrocyte (A) and blood vessel (V) compartment. B: Stimulation signal (Iext) input to the 
neuron to model the experimental 8s stimulation protocol. Random Gaussian noise was added to make 
it experimentally realistic. C: Astrocyte [Ca2+]i dynamics in response to 8s stimulation. D: EET released 
by the astrocyte compartment in response to increase in [Ca2+]i. E: Astrocytic TRPV4 channel current 
(I
TRPV4
) changes in response to 8s stimulation (produced by a combination of input from astrocyte [Ca2+]i 




Figure 6-3: Blood vessel compartment dynamics in response to 8 s stimulation with 5mM 
[glucose]
blood
. A: Schematic representation of computational model of neurovascular unit showing the 
neuron (N), astrocyte (A) and blood vessel (V) compartment. B: Stimulation signal (Iext) input to the 
neuron to model the experimental 8 s stimulation protocol. Random Gaussian noise was added to make 
it experimentally realistic. C: Simulated NO release in the blood vessel compartment in response to 
astrocyte evoked EET release. D: Simulated increase in the vessel diameter (vasodilation) in response 





6.3 The effect of high glucose on neurovascular coupling and neuronal firing: 
the role of TRPV4 feedback 
 
Various studies have demonstrated cerebral blood flow deficits in diabetic patients and animal 
models of diabetes (407, 408). It is speculated that these result in impaired NVC, however the 
underlying mechanisms remain unclear. Using the minimal model of NVC described above, I 
examined whether changing glucose levels in the vessel compartment reproduced the effect of 
hyperglycemia on NVC. Patients with poorly controlled diabetes have blood glucose levels of 
17-20 mM (409, 410). Thus, I applied an 8s stimulation to the model with glucose levels of 
20mM in the vessel compartment. Compared to simulations with 5mM glucose, 20mM glucose 
abolished the evoked NO levels in the vessel compartment and thus abolished vasodilation in 
response to neuronal stimulus (Figure 6-4B-C). As a result of reduced vasodilation under 
hyperglycemia, the increase in I
TRPV4
 seen in the astrocyte compartment under conditions of 
5mM glucose was also abolished by 20mM glucose (Figure 6-4D).  
I next examined whether the reduction in the TRPV4 current by 20mM glucose affected 
neuronal activity through vascular feedback, as would be predicted by the hemoneural 
hypothesis (150, 339). Simulated neuronal responses to an 8s stimulation under 20mM glucose 
conditions are shown in Figure 6-5B. 
 To observe any changes in the neuronal peaks with sufficient statistical power, I simulated the 
model for 50 trials and quantified peaks observed during the baseline and recovery time periods 
defined for the simulations similar to the experimental quantification in section 2.4.1). I found 
neuronal peak frequency during the response time period compared to the baseline and 
recovery did not differ between 5 mM and 20 mM glucose (Figure 6-5C). I then quantified the 
number of non-stimulus specific (NSS) peaks, defined as number of peaks observed during 
baseline and recovery time periods for 5mM and 20mM glucose over 50 trials. This showed a 
significant increase in the spike count in the 20mM glucose trials (Figure 6-5D). Together, 
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these data suggest that although the neuronal responses to 8 s stimulation are conserved in 
20mM glucose simulation, there is an increase in spontaneous neuronal firing following 
stimulation (similar to the increase in baseline neuronal Ca2+ peaks observed experimentally 






Figure 6-4: Blood vessel and astrocyte TRPV4 dynamics at 20mM [glucose]
blood
. A: Stimulation 
signal (Iext) input to the neuron to model the experimental 8 s stimulation protocol. Random Gaussian 
noise was added to make it experimentally realistic. B: I
TRPV4
 (TRPV4 channel current) in response to 
8 s stimulation in the presence of 5 mM (black) and 20 mM (red) glucose. C: [NO] in the blood vessel 
compartment in response to 8 s stimulation in the presence of 5 mM (black) and 20 mM (red) glucose.  
D: Blood vessel diameter changes (vasodilation) in response to 8 s stimulation in the presence of 5 mM 




Figure 6-5:  Neuronal compartment dynamics at 20mM [glucose]
blood
. A: Stimulation signal (Iext) 
input to the neuron to model the experimental 8 s stimulation protocol. Random Gaussian noise was 
added to make it experimentally realistic. B: Neuronal spikes in response to 8 s stimulation in the 
presence of 5 mM (black) and 20 mM (red) glucose. C: Quantification of neuronal membrane potential 
spike frequency (peaks/s) during baseline, response and recovery (n=50 simulation trials). D: 
Quantification of non-stimulus specific (NSS) spike count in the presence of 5 mM (black) and 20 mM 




6.4 The effect of 20mM glucose exposure on modelled synaptic plasticity: an 
STDP basis 
 
I next extended the model above to represent two neurons influenced by a single astrocyte and 
vessel (Figure 6-6A). This two neuron network model allows an examination and prediction 
of the effects of the neurovascular defects observed under hyperglycemic conditions, in 
particular the reduced vasodilation (from simulations, see section 6.3) or RBC speed (from 
experiments, see section 4.3) and increase in the NSS neuronal activity, on synaptic function. 
Using the standard STDP model for testing synaptic plasticity, I observed the change in the 
STDP weight throughout the course of 50 trials of training. On simulation, I found a decrease 
in synaptic weight during the course of training (50 trials) in the presence of 20mM glucose 
compared to 5mM glucose (Figure 6-6B). These data suggest a reduction in simulated STDP 





Figure 6-6: Effect of 20mM [glucose]
blood
 on modelled synaptic plasticity (STDP). A: Schematic 
representation of the two neuron (N1 and N2) model coupled to a single astrocyte and vessel via 
glutamate release (Glut) in the feedforward direction through the astrocyte (via EET) and feedback 
(TRPV4 activation) release of adenosine to the neurons. Neurons N1 and N2 are connected by synapse 
with connection strength or weight, w12 B: which is updated over the course of training (n = 50 trials) 







I have developed a computational model of the NVU that simulates neuronal dynamics as 
changes in the neuronal membrane potential, astrocyte [Ca2+]i vessel NO and diameter to 
simulate NVC at normal (5mM) and high (20mM) glucose levels. The parameters of the model 
are tuned to represent the observed biological time scales for the neuronal, astrocyte and vessel 
compartment. Although there have been several computational models of NVC (as described 
in section 1.12.1), none have modelled the effect of disease such as diabetes, which are known 
to be associated with micro- and macrovascular impairment in humans and with impaired 
cognition (as discussed in section 1.6). 
Using this model, I simulated responses in the neuron, astrocyte and vessel compartment which 
reliably reproduced the responses observed in the experimental zebrafish model of 
hyperglycemia in chapter 4.  Using an 8 s stimulation paradigm (similar to that applied to my 
experimental zebrafish model), I have simulated NVC, characterized by an increase in neuronal 
spiking frequency and associated vasodilation. The simulation results are similar to those 
characterized in the zebrafish model of NVC, in which 8s visual stimulation evoked an increase 
in neuronal membrane potential spikes and increase in RBC speed. In addition, the 
computational model was able to predict variables that cannot currently be easily measured in 
the zebrafish such as astrocyte [Ca2+]
i
, TRPV4 current and NO levels. To further validate the 
model, these predictions should be measured in future experiments (discussed in chapter 7). 
In chapter 4, I demonstrated the effect of hyperglycemia on NVC and suggested a possible 
role of NO in ameliorating the observed deficits. Although NO deficiency has been reported in 
both diabetes (411) and associated pathologies (412, 413), the mechanisms by which NO 
deficiency causes neurovascular deficits is unclear. Using the computational model, I predict 
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that high glucose levels (20 mM) leads to reduction in NO release in response to stimulation 
and a reduction in stimulus-evoked vasodilation in the 20mM glucose condition. This could 
explain the lack of RBC speed increase observed in the zebrafish (section 4.3). Using the 
computational model, I further show an effect of 20mM glucose on neuronal activity as a 
function of reduced TRPV4 current (339). This could be explained biologically by reduced 
expression of TRPV4 (section 4.11) or dysfunctional TRPV4 as an outcome of hyperglycemia. 
Further investigation is needed to investigate the mechanistic basis of these predictions of 
hyperglycemic TRPV4 reductions Finally, I have described the consequences of reduced 
vasodilation, reduced TRPV4 current and increased neuronal NSS activity on synaptic 
plasticity mechanisms. In the presence of 20mM glucose, the model predicts a reduction in the 
update of synaptic weight through a reduction in STDP, a marker of dysfunctional synaptic 
plasticity (see section 4). This effect of high glucose on synaptic plasticity mechanism, as 
predicted by the computational model in the present studies suggests future directions to design 
experiments testing effect of hyperglycemia on synaptic plasticity and learning. Dysfunctional 
synaptic plasticity is known to underlie cognitive defects such as learning, memory and choice 
preference (which I found to be altered by experimentally induced hyperglycemia in zebrafish, 
section 4.13).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
6.6 Conclusions 
 
Developing complementary computational models alongside experimental work can aid us in 
predicting the mechanisms underlying experimental observations. Furthermore, modelling 
complex disease pathologies can help predict possible interventions. This is important not only 
to increase our knowledge but to identify potential targets for drug discovery. 
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With the minimal computational model of the NVU presented, I have shown similar results to 
those obtained in my experimental model of NVC (chapter 4). Further, I have described the 
importance of NO in hyperglycemic dysfunction of NVC and, finally, proposed an influence 
of neurovascular function on synaptic plasticity. There are several advantages of developing 
simple computational models such as that in this thesis. Firstly, this helps to develop more 
biologically realistic single unit models to simulate and predict mechanisms of neurovascular 
and possibly hemoneural hypothesis. Secondly, simple minimal models are powerful tools to 
simulate neurovascular networks to show how single synaptic change could influence neuronal 
network activity (such as LFP, EEG) and also to simulate and predict the BOLD responses. 
Due to technical limitations, it is difficult to measure both deep brain capillary responses and 
surface arterioles alongside neuronal activity. Hence, complementing experimental data with 
computational modelling may help address such questions. 
There have been several computational models of NVC that aim to understand the mechanisms 
of NVC but there are no models that attempt the explain the physiology of disrupted NVC in 
diseases such as diabetes.  The minimal model shown here could be used as the foundation to 
add more vascular details such as modelling the endothelial calcium response and dynamics of 
glucose metabolism to describe further the disease pathology and its effect on the NVU.  
The computational model presented here is simulated to show the effect of 20mM glucose on 
NVC but can be extended to simulate the effects of various factors such as gch1 on NVC. In 
general, with the basic minimal computational model described in the present study, the effect 
of various interventions on the NVC could be studied to allow further prediction of the effect 





7 General Discussions: On the importance of neurovascular 




 NVC refers to increases in local cerebral blood flow to maintain energy supply to activated 
neurons. NVC in rodents is measured invasively through a window surgically created in the 
skull (414, 415). Furthermore, anaesthesia is required to perform the neurovascular 
measurements, making these less physiological and introducing confounding influences on 
neuronal activity and vascular tone. To circumvent these constraints, I developed a non-
invasive zebrafish model of NVC that exploits their optical transparency and ease of genetic 
and pharmacological manipulation. Using lightsheet microscopy, I showed that NVC can be 
detected and quantified in unanesthetized transgenic zebrafish larvae at 8 dpf. Similar to the 
mammals, zebrafish larvae display spatiotemporal specificity of NVC which develops at a 
specific developmental stage (between 6-8 dpf).  Studies have shown various underlying 
mechanisms of NVC in rodents including direct NO based modulation of cerebral blood blow 
by interneurons (26), neuronally evoked astrocytic release of vasoactive substance (through 
COX) (38) and more recently the involvement of pericytes in controlling capillary diameter 
(82). I have demonstrated the existence of both NO based modulation and COX based 
mechanism of NVC in zebrafish, suggesting the mechanisms of NVC are conserved between 
mammals and zebrafish and validating zebrafish as a tool for investigating the mechanisms of 
NVC. I have shown the utility of this model for investigating neurovascular dysfunction in 
vascular and neurodegenerative pathologies (diabetes and gch1 loss-of-function specifically). 
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NVC is suggested to be affected in a plethora of neurological disorders and increasingly is 
associated with dementia (section 1.5). Studies investigating pathological mechanisms of AD 
and PD have shown reductions in cerebral blood flow (416-418). Recent studies have proposed 
various vascular diseases to be major risk factors for neurodegeneration (169, 203). Diabetes 
forms a major burden of vascular disease and diabetics are reported to be at increased risk of 
cognitive defects (419). Animal studies have shown reduction in stimulus associated 
vasodilation in the cerebral blood vessels with experimentally induced diabetes (244). Other 
studies have shown hyperglycemia associated NVU defects including activation of 
inflammatory markers in the brain and increased production of reactive species (199), pericyte 
drop-out (79) and increased blood brain barrier permeability (420). However, whether these 
deleterious changes cause defective NVC is unclear. Using my zebrafish model of NVC, I 
confirmed the negative consequences of 20mM glucose exposure (levels seen in poorly 
controlled diabetics) on both the anatomy and function of the NVU. The vascular phenotypes 
induced by glucose exposure included reduced RBC speed, impaired NVC, reduction in 
vascular anatomical features such as number of branchpoints, vascular length and vessel radius 
(see chapter 4). Glucose exposure affected various components of the NVU including 
increased expression of glial specific GFAP, GS, iGluSnFR and TRPV4, decrease in 
endothelial claudin5a and klf2a, reduction in number of sm22ab positive mural cells (including 
pericytes and smooth muscle cells) and reduced vascular NO. While all these glucose-induced 
defects have been detected in previous studies in other models, it has not been clear whether 
these defects are a resultant of NO bioavailability. In the present study, I also showed that co-
treating glucose exposed zebrafish larvae with a NO donor SNP ameliorated all the deleterious 
effects of glucose suggesting an active role of NO in maintaining the function of NVC.  All of 
these findings are summarised in Figure 7-1. SNP is commonly used for treating hypertension 
however its ability to treat diabetes related neurovascular dysfunction has not been tested. Thus, 
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my work suggests a possible NO based therapeutic treatment for diabetes which should be 





Figure 7-1: Schematic representation of the effect of hyperglycemia on neurovascular unit. A: 
Cross section of the neurovascular unit showing various markers tested in the zebrafish model under 
normoglycemia. B: Cross section of the neurovascular unit showing alterations of various markers 




Gch1 plays an important role in producing an essential cofactor BH4 for NOS and also 
synthesis of monoaminergic neuromodulators such as serotonin and dopamine (396, 400) 
Various studies have shown gch1 mutations are associated with PD (184, 185). Interestingly 
gch1 knockout mice develop cardiovascular complications including pulmonary hypertension, 
diabetes, atherosclerosis and neuropathy (403). Using the novel zebrafish gch1 mutants 
developed by Dr. Marcus Keating, I demonstrated these homozygous mutants display impaired 
NVC and cerebrovascular patterning. Supplementing NO (using SNP) ameliorated these 
defects. I speculate that SNP induced vasodilation and angiogenesis to maintain neurovascular 
function. The ability of a NO donor to rescue the effect of both hyperglycaemia and gch1 
mutation is fascinating and points to the central role of NO in neurovascular health. To date, 
there are no NO-based treatments for diseases associated with neurovascular dysfunction. This 
further emphasizes the potential for therapeutic strategies that target the cerebral vasculature 
and its function. Moore and Cao (150) in their seminal hemoneural hypothesis suggested 
vascular derived NO to be one possible way in which vasculature could modulate the neuronal 
activity.  
To understand the cognitive and behavioural defects observed in various pathologies, it is 
essential to understand how these affect synaptic plasticity. Synaptic plasticity measurements 
involve measuring STDP in response to a stimulus. Using a minimal computational model of 
NVU, I demonstrated that NO can modulate vessel diameter, thereby influencing the activity 
of astrocytes through mechanical activation of TRPV4 (as established by (160, 338)). Further 
changes in astrocyte activity can modulate neuronal firing threshold through release of 
adenosine (160). This mechanism of vascular feedback could be disrupted in pathologies with 
NO deficiency such as diabetes and PD. Through the computational model proposed in the 
present study, I have proposed that disrupted vascular feedback under simulated hyperglycemic 
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conditions (20mM glucose), results in increases in non-stimulus specific neuronal activity 
which could disrupt the temporal relation between pre- and post-synaptic neurons in a two 
neuron model, thereby affecting synaptic plasticity. Disrupted synaptic plasticity is associated 
with learning and memory deficits and could thus underlie the cognitive defects associated with 
various disease pathologies.  
 
7.2 Limitations and Future work 
 
In the first part of my thesis, I developed a novel model of NVC in 8 dpf old zebrafish that can 
be used in future to investigate further unknown mechanisms. Future work using this model 
would involve investigating NVC in response to higher stimulus frequencies similar to that 
used in mammalian research. On similar lines to mammalian models, NVC could be 
investigated in different areas of the zebrafish brain and/or using different stimulus modalities. 
Within the constraint of a closed set up LSFM used in the present study, visual stimulus was 
the most practical and robust methodology to be used to investigate NVC.  However, future 
research could combine open SPIM with auditory/ mechanical stimuli to investigate NVC in 
the forebrain/hindbrain. Amongst the various NVC mechanisms suggested, it is now known 
that NVC in the cerebellum is predominantly neuronal NO driven (26) and astrocyte derived 
prostaglandin driven in the cortex (38). Thus it would be interesting to see if such area specific 
mechanisms exist in zebrafish.  
There is an ongoing debate about the contribution of various neuronal subtypes to NVC in the 
mammalian brain. Various studies have established that vasodilation in somatosensory cortex 
is mediated by excitation of glutamatergic neurons (375). Multiple reports have shown the 
existence of center-surround (dilation) and contra-ipsilateral (constriction) patterns of 
hemodynamics in the somatosensory cortex in response to sensory stimulation correlating the 
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strength of constriction in the surrounding region to the strength of inhibition (421-423). 
Various recent studies have established various different interneurons messengers to be 
involved in dilation or constriction of the cortical microvessels. Studies by Cauli et al. (424) 
have described the role of NO and vasoactive intestinal peptide release in vasodilation in the 
somatosensory cortex. On the contrary multiple reports have shown interneurons to release 
factors such as somatostation and neuropeptide-Y causing vasocontriction (424, 425).  
However, the specific contribution of any/each of these to cortical BOLD responses is yet to 
be resolved. The ease of genetic manipulation in zebrafish systems and the NVC model 
(described in the present thesis) provides an opportunity to investigate the contribution of 
specific neuronal subtypes (particularly the various types of interneurons) to NVC. Future 
research to develop neuronal subtype specific zebrafish optogenetic line and/or tamoxifen 
inducible tissue specific lines would help resolve the ongoing debate of the cell type specificity 
of NVC regulation.  
I have shown non-specific NOS (nNOS, eNOS, iNOS) and COX (1 and 2) inhibition causes 
neurovascular uncoupling in zebrafish. However, the contribution of different NOS and COX 
isoforms to NVC is still unclear in mammals. Thus, future experiments with specific 
nNOS/eNOS/iNOS/COX1/COX2 inhibitors could establish the contribution of each. 
Furthermore, due to the constraint of most of the cellular calcium reporters existing as 
GCaMPs, it was difficult to visualize glial/endothelial calcium along with neuronal calcium 
changes. It would be interesting to use RCaMP2 (Red encoded calcium indicator) based 
transgenics to facilitate multicellular calcium imaging (426). Future studies with developing 
compound transgenic lines such as GFAP:RCaMP could help determine the role of radial glial 
cells in NVC (and thus their functional similarity to astrocytes).  
Zebrafish are commonly used to study the contribution of various genes to vascular 
development (427). Combining gene editing technologies such as Crispr-Cas9 based gene 
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knock-out/knock-in (428) with the zebrafish model of NVC would allow examination of the 
genetic basis of NVC. This would also help understand the relation between genetic risk factors 
for human neurological disease (such as apoE, (429)) and also similarities/differences 
compared to NVC in mammalian models.  
In the second part of my thesis, I used the zebrafish model of NVC to understand the importance 
of NO in hyperglycemia. A constraint of the present model of hyperglycemia was the inability 
to accurately measure blood glucose levels in larval zebrafish. To address this and also to 
completely investigate NVC in diabetes as a whole disease, future studies could be carried out 
with streptozotocin injection to induce diabetes (189). Due to the difficulty of injecting drugs 
at the larval form it was not used in this study. However, future research could examine NVC 
in adult zebrafish models where the streptozotocin injected method for inducing diabetes is 
established (430). This is also important to make zebrafish models more comparable to 
mammalian models wherein NVC is investigated in adult forms. Another method of studying 
NVC in diabetic models is to study NVC in pdx-1 zebrafish mutants having reduced β-cells, 
decreased insulin and elevated glucose (431).  This will also allow testing of novel NO based 
therapeutics in diabetes as a disease and not just glucose exposure. While I have shown the 
positive recovery effects of SNP, future investigations with other NO donors would establish 
the potential of NO based drugs for diabetes related treatments. 
The behavioural improvements demonstrated with SNP treatment further provide exciting 
avenues for further research into the links between NO and behaviour/cognition. However, 
more detailed behavioural characterization should include other cognitive tests such as novel 
object recognition (NOR) (306) or spontaneous alteration burst (SAB) behaviour (432), which 
are common tests for hippocampal function (433). These would complement future studies 
investigating NVC in different brain areas under normal and disease states.  
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Presence of an eNOS orthologue in zebrafish is currently debated. While genetic studies have 
established that zebrafish do not possess eNOS, I have shown positive NO reactivity in the 
zebrafish vasculature using DAF-FM staining (section 4.6). I speculate that this NO reactivity 
could be a resultant of a zebrafish specific NOS whose existence, similarity/difference with 
respect to mammalian forms needs further investigation. Furthermore, it would be interesting 
to evaluate changes in NO during NVC (normal/hyperglycemic) and its relation to calcium 
signalling in vascular ECs and various other cells of the NVU. NO is also commonly known 
as a mediator of 0.1 Hz vessel oscillations called vasomotion (434) that are independent of 
heart rate and are affected in several diseases such as diabetes and AD (435, 436). Thus, 
investigating NO dynamics may help understand the relation of vasomotion to such diseases.  
In the third part of my thesis, I extended the use of zebrafish model of NVC to study the effect 
of the PD related gene, gch1 and excitingly show recovery of NVC with SNP treatment. 
Understanding the mechanisms of NVC disruption and positive effects of SNP in gch1 mutants 
requires assessment of various NVU markers (such as blood brain barrier permeability markers, 
endothelial markers, mural cell coverage, glial cell reactivity) over the course of development 
from 4-9 dpf. This would help understand the factors that contribute to the onset of the 
pathology in the homozygous mutants.  
I have also described the positive effects of SNP on the locomotion defects observed in the 
homozygous gch1 mutants. This needs further investigation if the effects of SNP treatment can 
increase survival rates in the mutants. It would be interesting to investigate cognitive correlates 
such as light/dark preference, NOR and SAB in homozygous mutants with or without SNP 
treatment to correlate it to memory and/or hippocampal function.  Furthermore, as mentioned 
earlier, to test if NO based drugs could be quintessential in improving effect of PD pathologies, 
future work is needed to test the effect of other NO donors.  
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In the last part of my thesis, I described a computational model simulating the effects of 
hyperglycemia and predicting related NVC defects (similar to that observed in experimental 
hyperglycemia). A future direction of this model would be to simulate the effects of SNP in 
ameliorating hyperglycemic effects of NVC. 
The model described in the thesis has minimal parameters to describe the biological findings 
in the simplest possible framework but provides a foundation upon which to build a more 
complex model including other biological components as and when they are discovered. For 
example, the model can be developed further by adding equations representing pericyte and 
smooth muscle cell intracellular calcium changes. A limitation of the computational model is 
that the predicted vascular read out is diameter change and not RBC speed which limits its 
comparisons to the experimental data in this thesis. This is due to the uncertainty of zebrafish 
parameters such as blood pressure, resistance and viscosity. Future attempts to add various 
vascular parameters (such as intramural pressure, resistance), could help estimate RBC speed 
and also to simulate network of vessels connected in a similar way to VAN (328) and predict 
BOLD responses. Furthermore, scaling the whole NVU to the network would help predict 
changes in neuronal network parameters (such as EEG/LFP) under hyperglycemia. This could 
suggest possible EEG based biomarkers to aide prognosis of diabetes and related disorders. A 
neurovascular network model can also be used to simulate learning and cognitive defects 
associated with such disease. In general, a computational model of NVC with the scope to 
model disease can help understand the parametric difference that could underlie observations 
from animal models.  
To conclude, I have first demonstrated a novel zebrafish model to investigate NVC followed 
by showing neurovascular uncoupling under various disease pathologies such as 
hyperglycemia and gch1 mutation (related to cardiovascular complications and PD). To 
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understand the commonality of the mechanisms between these two pathologies, future research 
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